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ABSTRACT 
 
CYTOCHROME P450 MONOOXYGENASE-MEDIATED LIPID METABOLISM IN 
OBESITY AND COLON TUMORIGENESIS 
 
SEPTEMBER 2019 
 
 
WEICANG WANG, B.S., NORTHWEST A&F UNIVERSITY 
 
M.S., EAST CHINA NORMAL UNIVERSITY 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Guodong Zhang 
 
 
Colon cancer is a major public health issue: it is expected to have 140,250 new cases and 
50,630 deaths during 2018, making colon cancer the third most common type of cancer 
and the second leading cause of cancer death in the United States. Obesity is associated 
with enhanced colonic inflammation, which is a major risk factor of colorectal cancer. 
Currently, more than 35% of adults and nearly 17% of children are obese. Considering 
the obesity and colon cancer epidemic in the United States, there is an urgent need to 
identify novel therapeutic targets for obesity and colon cancer. Here, using a LC-MS/MS-
based lipidomics approach and disease mouse models, we found that: 1) CYP 
monooxygenase and its-derived fatty acid epoxides are decreased in adipose tissues in 
HFD-induced obese mice; 2) CYP monooxygenase and its-derived fatty acid epoxides 
are upregulated in AOM/DSS-induced colon cancer; pharmacological inhibition or 
genetic ablation of CYP monooxygenase attenuates AOM/DSS-induced colon cancer in 
mice; 3) Dietary feeding of ω-3 PUFAs-rich diets increased levels of CYP-derived EDPs 
 x 
in both plasma and MC38 colorectal tumor of the treated mice, systematic treatment with 
EDPs suppressed growth of MC38 colorectal tumor in mice. Together, these results 
support that previous unappreciated CYP lipid metabolism pathway plays a vital role in 
the development of obesity and colon cancer. Moreover, our study identifies the major 
enzymes and their metabolites in CYP lipid metabolism pathway as novel therapeutic 
targets for treating obesity and colon cancer. 
 
Key words: Lipid Metabolism, Cytochrome P450 Monooxygenase, Obesity, Colon 
Tumorigenesis 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Background 
The enzymatic metabolism of polyunsaturated fatty acids (PUFAs), such as arachidonic 
acid (ARA, 20:4ω-6), leads to formation of bioactive lipid metabolites (LMs), which are 
important lipid signaling molecules involved in regulation of many fundamental 
physiological and pathological processes 1-3. There are three major pathways involved in 
enzymatic metabolism of PUFAs: cyclooxygenase (COX-1 and COX-2), lipoxygenase 
(5-LOX, and 12/15-LOX), and cytochrome P450 (CYP). The COX pathway leads to 
formation of prostaglandins, which are important mediators to induce inflammation and 
pain; and COX-2 is the therapeutic target of many anti-inflammatory drugs on the market 
1. The LOX pathway produces leukotrienes and hydroxyl fatty acids, which are 
predominately pro-inflammatory and play critical roles in inflammatory diseases such as 
asthma 1. The CYP pathway converts PUFAs to fatty acid epoxides, which have a variety 
of beneficial effects such as anti-inflammatory, cardio-protective, vasodilative, and 
analgesic actions 2,3. Besides ARA, other PUFAs, including linoleic acid (LA, 18:2ω-6), 
α-linolenic acid (α-LA, 18:3ω-3), γ-linolenic acid (γ-LA, 18:3ω-6), dihomo-γ-linolenic 
acid (DGLA, 20:3ω-6), eicosapentaenoic acid (EPA, 20:5ω-3), and docosahexaenoic acid 
(DHA, 22:6ω-3), are also efficient alternative substrates of these enzymes and are 
converted to the corresponding LMs with unique biological activities 3-5. Together, this 
leads to formation of a large array of LMs with diverse chemical structures, many of 
which have potent biological activities. 
 2 
Colon cancer is a major public health issue: it is expected to have 140,250 new cases and 
50,630 deaths during 2018, making colon cancer the third most common type of cancer 
and the second leading cause of cancer death in the United States 6. It is important to 
identify novel therapeutic targets of colon cancer, in order to develop effective methods 
for prevention and/or treatment of colon cancer. Substantial studies have shown that the 
metabolites, enzymes, and receptors involved in the eicosanoid signaling contribute to the 
carcinogenesis of colon cancer. It would be important to discover novel therapeutic 
targets from the eicosanoid signaling cascade, especially previously unappreciated CYP 
lipid metabolism pathway, in order to develop novel agents to reduce the risks of colon 
cancer. 
 
Obesity is another serious public health threat over the past decades in US: currently, more 
than 35% of adults and nearly 17% of children are obese 7,8. Obesity is associated with 
enhanced colonic inflammation 9-11, which is a major risk factor for developing colorectal 
cancer 12. Indeed, obese individuals have a 30-60% greater risk of developing colorectal 
cancer 13,14. Emerging research supports the notion that the eicosanoid signaling is 
deregulated in obesity and plays critical roles in the pathogenesis of obesity 15,16. However, 
the detailed function of CYP lipid metabolism pathway in obesity and obesity-induced 
colonic inflammation are unknown. Considering the obesity epidemic and the potential 
lethal consequence of obesity-enhanced colorectal cancer, it is important to identify novel 
therapeutic targets in CYP lipid metabolism pathway for obesity and its-induced colonic 
inflammation. 
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1.2 Objectives 
A number of studies have confirmed the importance of inflammatory mediators, 
particularly inflammatory cytokines and eicosanoids, in the pathogenesis of obesity and 
colon cancer. Previous study focus on COX and LOX pathway, however, the function of 
CYP lipid metabolism pathway in the obesity and colon cancer is still unknown. The 
objective of this thesis is to determine the contribution of CYP lipid metabolism pathway 
in progression of obesity and colon cancer.  
 
To achieve our objective, we propose the following four research projects:  
 
Research Project1: Determine the novel biomarkers or therapeutic targets from 
CYP lipid metabolism pathway during obesity. 
In research projects 1, we will perform three key experiments: we will (1) feed the mice 
with HFD to induce obesity; (2) conduct a LC-MS/MS-based lipidomics analysis on 
adipose tissue to explore the profiles of LMs from COX, LOX and CYP metabolizing 
pathways; (3) perform the gene expression analysis of major metabolizing enzymes in 
CYP lipid metabolism pathway. 
 
Research Project 2: Determine the novel biomarkers or therapeutic targets from 
CYP lipid metabolism pathway in AOM/DSS-induced colon tumorigenesis. 
In research projects 3, we will perform six key experiments: we will (1) treat the mice 
with AOM and DSS to induce colon cancer; (2) conduct a LC-MS/MS-based lipidomics 
analysis on colon tissue from cancer mice to explore the profiles of LMs from COX, 
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LOX and CYP metabolizing pathways; (3) perform the gene expression analysis of major 
metabolizing enzymes in CYP lipid metabolism pathway; (4) test the effect of 
pharmacological inhibition of CYP on AOM/DSS-induced colon tumorigenesis; (5) test 
the effect of genetic knockout of CYP on AOM/DSS-induced colon tumorigenesis; (6) 
test the effect of CYP-derived EpOMEs on AOM/DSS-induced colon tumorigenesis. 
 
Research Project 3: Determine the actions of ω-3 PUFAs-derived eicosanoid 
metabolites on colorectal cancer. 
In research projects 3, we will perform four key experiments: we will (1) establish the 
xenograft MC38 colorectal cancer growth model in C57BL/6 mice; (2) study the effect of 
ω-3 PUFAs on MC38 colorectal cancer growth by feeding the mice with control ω-6 diet 
(ratio of ω-6-to-ω-3 PUFA is ≈ 69.3:1), ω-3 diet (ratio of ω-6-to-ω-3 PUFA is ≈ 1.26:1), 
or ω-3-high diet (ratio of ω-6-to-ω-3 PUFA is ≈ 0.56:1); (3) conduct a LC-MS/MS-based 
lipidomics analysis on plasma, tumor and colon tissues from cancer mice to explore the 
profiles of LMs from COX, LOX and CYP metabolizing pathways; (4) test the effect of 
EDPs on MC38 colorectal cancer growth in mice. 
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CHAPTER 2 
 
 LITERATURE REVIEW 
 
2.1 Lipid signaling and colorectal cancer 
Colorectal cancer (CRC) is the third most common cancer and the second leading cause 
of cancer-related deaths in the US 6, emphasizing the need for discovering novel cellular 
targets which are crucial in the pathogenesis of CRC. Colonic inflammation is a major 
risk factor for developing CRC, therefore, targeting the pathological components 
involved in colonic inflammation is a promising strategy to reduce the risks of CRC 17. 
Eicosanoids, which are endogenous lipid signaling molecules produced from enzymatic 
metabolism of polyunsaturated fatty acids (PUFAs), play essential roles in inflammatory 
responses and were recently implicated in cancer 18,19. The most prominent CRC-
associated eicosanoids are prostaglandins, which are produced by the cyclooxygenase-2 
(COX-2) enzyme that is overexpressed in most human CRC samples 19. Genetic 
knockout of Cox-2 reduces polyp formation in azoxymethane (AOM)- or Apc mutation-
induced CRC models 20,21. Furthermore, clinical and epidemiological studies support that 
pharmacological inhibitors of COX-2, such as nonsteroidal anti-inflammatory drugs 
(NSAIDs), are effective in reducing the risk of CRC 19, supporting the critical importance 
of eicosanoid signaling in CRC. However, the gastrointestinal and cardiovascular 
toxicities induced by the COX-2 inhibitors have limited their clinical applications 22. 
Besides COX-2, the roles of other eicosanoid pathways in colonic inflammation and CRC 
are not well understood 23. It is therefore important to discover novel eicosanoid signaling 
pathways involved in tumorigenesis. 
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Figure 2.1 A simplified scheme of PUFA metabolism to generate bioactive lipid 
metabolites (LMs). There are three major metabolizing pathways: cyclooxygenase 
(COX), lipoxygenase (LOX), and cytochrome P450 (CYP). 
 
Besides being substrates of COX-2, PUFAs are also substrates of cytochrome P450 
(CYP) monooxygenases (predominately CYP2C and CYP2J isoforms), which convert 
them to epoxygenated fatty acids (EpFAs). EpFAs include epoxyeicosatrienoic acids 
(EETs) produced from arachidonic acid (ARA, 20:4ω-6), epoxyoctadecenoic acids 
(EpOMEs) from linoleic acid (LA, 18:2ω-6), epoxyoctadecadienoic acids (EpODEs) 
from α-linolenic acid (ALA, 18:3ω-3), and epoxydocosapentaenoic acids (EDPs) from 
docosahexaenoic acid (DHA, 22:6ω-3) 2. EpFAs are metabolically unstable with a half-
life of several seconds in vivo, in part because they could be rapidly metabolized by 
soluble epoxide hydrolase (sEH) to generate the corresponding fatty acid diols 3. 
Currently the CYP eicosanoid pathway is being explored by academic laboratories and 
pharmaceutical companies for clinical applications. For example, GlaxoSmithKline is 
conducting human clinical trials to test an sEH inhibitor GSK2256294; the company has 
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found that this drug candidate is well-tolerated and causes sustained inhibition of sEH in 
humans 24. Other novel classes of sEH inhibitors are also being considered for human 
trials 25. In addition, recent studies have shown that some FDA-approved drugs are potent 
inhibitors of CYP monooxygenases 26.  
 
Emerging research supports that the CYP pathway plays critical roles in regulating 
inflammation, angiogenesis, tumor growth, and tumor metastasis 27-30, and could be 
involved in the pathogenesis of colonic inflammation and CRC 31-34. A better 
understanding of the roles of this previously unappreciated pathway in the pathogenesis 
of CRC could help to develop new strategies for cancer treatment or prevention. In this 
review, we will discuss recent studies of the roles of the CYP eicosanoid pathway in the 
pathogenesis of CRC. 
 
2.2 Expression of CYP monooxygenases in colonic inflammation and CRC 
Previous studies have shown that CYP monooxygenases are overexpressed in CRC. 
Enayetallah et al. reports that CYP2C9 is detected in 13 out of 17 human colon tumor 
samples, while it is not detected in matched benign samples 35. Consistent with the human 
data, our recent study have shown that the expressions of CYP monooxygenases are 
increased in colon tumor tissues and colon cancer cells 34. Compared with untreated 
control mice (healthy mice), the expressions of mouse CYP monooxygenases, such as 
Cyp2c38, Cyp2c39, Cyp2c55, Cyp2c65, Cyp2c70, Cyp2j6, Cyp2j9, and Cyp2j13, are 
increased in colon tissues of AOM/ dextran sulfate sodium (DSS)-treated CRC mice 34. In 
addition, the concentrations of CYP-produced EpFAs are increased in the plasma and 
colon tumors of AOM/DSS-induced CRC mice 34. Furthermore, we find that compared 
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with normal human colon cells (CCD-18co), the expression of CYP2C8, CYP2C9, 
CYP2C19, and CYP2J2 is increased in human CRC cells (HCT116 and Caco-2) 34. Few 
studies have investigated the expression of CYP monooxygenases in colonic 
inflammation. Willenberg et al. reported that in DSS-induced colitis models, the 
circulating concentrations of EpFAs are not changed 36, suggesting that the CYP 
eicosanoid pathway is not altered in DSS-induced colitis. Together, these results support 
that CYP monooxygenases are overexpressed in CRC. 
 
In addition to CRC, previous studies have shown that CYP monooxygenases are 
overexpressed in other tumor tissues, such as breast, liver, and stomach tumors. There 
could be many mechanisms by which CYP monooxygenases are overexpressed in tumor 
tissues 29,35. The expression of CYP monooxygenases has been shown to be elevated by 
hypoxia 3, which is a common feature of tumor tissues 37. It is feasible that the hypoxic 
tumor microenvironment could contribute to the increased expression of CYP 
monooxygenases in tumor tissues. 
 
2.3 Roles of CYP eicosanoid pathway in colonic inflammation and CRC  
Recent studies also support the critical roles of CYP monooxygenases in tumorigenesis. 
In a xenograft tumor model, overexpression of human CYP2C8 or CYP2J2 in endothelial 
cells led to increased xenograft tumor growth of B16F10 melanoma and T241 
fibrosarcoma 28. Using a Lewis lung carcinoma (LLC) resection-induced tumor 
metastasis model, endothelial expression of human CYP2C8 or CYP2J2 increases lung 
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metastases 28. Together, these results support the pro-tumorigenic and pro-metastatic 
effect of CYP monooxygenases.  
 
Our recent studies also support a potential role of CYP monooxygenases in the 
tumorigenesis of CRC 34. Compared with AOM/DSS-induced Cyp2c+/+ mice, the 
AOM/DSS-induced Cyp2c+/- mice have lower tumor numbers and total tumor burden, as 
well as reduced expression of CYP monooxygenases and concentrations of CYP-derived 
fatty acid epoxides in colon tissues, supporting the roles of Cyp2c monooxygenases in 
colon tumorigenesis 34. Consistent with the results observed in transgenic mouse models, 
we also find that pharmacological inhibition of CYP monooxygenases suppresses 
AOM/DSS-induced colon tumorigenesis in mice 34. Together, these results support that 
CYP monooxygenases contribute to the tumorigenesis of CRC.  
 
Recent research has shown that sEH plays a critical role in colonic inflammation and 
CRC. In  DSS-induced colitis and CRC model, sEH-/- mice have reduced colonic 
inflammation (as assessed by mucosal erosion and lymphoplasmocytosis) and 
carcinogenesis (tumor incidence and volume) compared with wild-type mice 31. 
Similarly, in an interleukin 10 (IL-10) deficiency-induced CRC model, sEH-/- IL-10-/- 
mice have reduced colonic expression of pro-inflammatory cytokines and formation of 
ulcers and carcinomas compared with sEH+/+ IL-10-/- mice 32,33. Together, these results 
support that sEH could contribute to colonic inflammation and inflammation-associated 
CRC. This is largely in agreement with previous studies which show that inhibition of 
sEH reduces inflammatory responses in various disease models. For example, in obese 
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mice, pharmacological inhibition of sEH reduces the infiltration of macrophages and 
expression of pro-inflammatory cytokines in epididymal fat and liver 38,39. Deletion of 
sEH also leads to reduced infiltration of neutrophils, decreased levels of pro-
inflammatory cytokines and less neuronal damage in an intracerebral hemorrhage mouse 
model 40. Together, these studies demonstrate sEH is involved in many inflammation-
associated diseases. 
  
More studies are needed to better characterize the roles of sEH in cancer. Panigrahy et al. 
have shown that pharmacological inhibition or genetic deletion of sEH increases tumor 
growth and metastasis in xenograft models by stimulating tumor angiogenesis 28. 
However, this finding is different from the results observed in the DSS and IL-10-/- 
mouse models 31-33. The different results could be, at least in part, due to the differences 
in mouse models. The phenotypes in the DSS and IL-10-/- mouse models are strongly 
associated with inflammation, therefore, inhibition of sEH would reduce inflammatory 
response and attenuate inflammation-associated CRC 31-33. In other models such as 
xenograft models, inhibition of sEH could upregulate angiogenesis and increase 
tumorigenesis 28. However, we have to mention that the pro-angiogenic effects of sEH 
inhibition are mainly observed in mouse models 28. A recent human clinical trial has 
shown that even at 100% inhibition of sEH, there is no change of the plasma 
concentration of vascular endothelial growth factor (VEGF), which is an important 
biomarker of angiogenesis 24. Since sEH inhibitors are currently being evaluated in 
human clinical trials 24,25, it is of critical importance to better understand the roles of sEH 
and sEH inhibitors in tumorigenesis.  
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2.4 Effects of CYP-produced eicosanoids on colonic inflammation and CRC 
The metabolism of PUFAs by CYP monooxygenases leads to the formation of EpFAs 2. 
The major EpFAs in tissues and plasma include EpOMEs produced from LA, EETs from 
ARA, and EDPs from DHA. Emerging research supports that these eicosanoid 
metabolites have potent effects on tumorigenesis with the details discussed below. 
 
Previous studies show that EpOMEs have a series of detrimental actions such as inducing 
chemotaxis, inflammation, cardiovascular diseases, and pulmonary injury 41-46. In human 
studies, EpOMEs, which are termed “leukotoxins,” are associated with multiple organ 
failures and adult respiratory distress syndrome in severe burn patients 42,44,47. Notably, at 
a concentration as low as 10 nM, EpOMEs enhance neutrophil chemotaxis, suggesting 
potent pro-inflammatory effects of EpOMEs 46. EpOMEs can be further metabolized by 
sEH to form the corresponding fatty acid diols termed dihydroxyoctadecenoic acids 
(DiHOMEs) 3. Similar to EpOMEs, DiHOMEs have also been shown to induce 
chemotaxis, tissue injury, and cause mortality in animal models 47,48. Together, these 
results show that metabolism of LA by CYP monooxygenases leads to the formation of 
pro-inflammatory eicosanoid metabolites (EpOMEs and DiHOMEs). In our recent study, 
we find that the administration of 12,13-EpOME exaggerates AOM/DSS-induced CRC in 
mice 34, supporting that EpOMEs could enhance the development of CRC.  
 
The biological actions of EETs are more complicated, as they have been shown to have 
anti-inflammatory effects (negatively associated with tumorigenesis) and pro-angiogenic 
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effects (positively associated with tumorigenesis). Indeed, many studies have shown that 
EETs have potent anti-inflammatory effects. In a murine carotid artery model, treatment 
with 11,12-EET decreases tumor necrosis factor-α (TNF-α)–induced mononuclear cell 
adhesion to the arterial endothelium 49. Treatment with 14,15-EET inhibites TNF-induced 
degradation of IκBα in primary human lung tissue 50 and reduces LPS-activated IL-1β 
and TNF-α expression in mouse macrophages 31. Together, these results support the anti-
inflammatory effects of EETs. The effects of EETs on tumor inflammation are not well 
characterized and require more studies. Previous studies have shown that inhibition or 
deletion of sEH attenuates DSS- or IL-10 knockout-induced CRC 31-33; these results could 
be, at least in part, due to the anti-inflammatory effects of EETs. On the other hand, EETs 
have pro-angiogenic effects, and therefore could promote tumor growth and metastasis. 
In an orthotopic cancer model, treatment of 14,15-EET at a dose as low as 15 μg/kg/day 
for 28 days increases orthotopic PC3M-LN4 prostate tumor growth in SCID mice 28.  In 
transgenic adenocarcinoma of the mouse prostate (TRAMP) mice, administration of 
14,15-EET at a dose of 15 μg/kg/day promotes prostate tumor growth, suggesting that 
EETs increase tumor growth in vivo 28. In addition, treatment with 14,15-EET increases 
tumor metastasis in a LLC resection model 28. More studies are needed to further 
characterize the role of EETs in tumorigenesis. 
 
Opposite to the effects of EpOMEs and EETs, our studies have shown that ω-3 PUFA-
produced EDPs inhibit angiogenesis, tumor growth, and tumor metastasis 51. 19,20-EDP 
inhibits tube formation, migration, and production of matrix metalloproteinases (MMPs) 
in endothelial cells, and suppresses VEGF- and basic fibroblast growth factor (bFGF)-
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induced angiogenesis in a Matrigel plug assay in mice, demonstrating its anti-angiogenic 
effect 51. Treatment with stabilized 19,20-EDP also suppresses primary tumor growth and 
tumor metastasis in mice 51. Consistent with our results, a recent study by Yanai et al. has 
shown that systematic treatment with EDPs inhibits pathological angiogenesis in a mouse 
model of macular degeneration 27. Furthermore, our recent study has shown that 
treatment with EDPs suppresses growth of MC38 colon tumors, supporting the anti-CRC 
effects of EDPs 52. 
 
To date, the molecular mechanisms for the biological actions of EpFAs are not well 
understood. Many eicosanoids act by binding to specific cellular targets. For example, 
COX-2-produced prostaglandin E2 (PGE2) and lipoxygenase (LOX)-produced 
leukotriene B4 (LTB4) act by binding to their G-protein coupled receptors 1. The direct 
cellular target(s) of CYP monooxygenase metabolites are not well understood, hampering 
our understanding of their mechanisms of action. Previous studies show that EETs bind 
to cell membrane-bound proteins in a high-affinity, specific, and saturable manner 53-55, 
and some of the biological actions of EETs are G protein-dependent 55-58. These results 
support that the CYP monooxygenase metabolites also act via interactions with specific 
cellular proteins; however, the identities of the cellular targets are not well understood. 
Beyond EETs, no study has investigated the cellular targets of other CYP 
monooxygenase metabolites (such as EpOMEs). Identification of their direct cellular 
targets could greatly enhance our understanding for the molecular mechanisms of the 
CYP monooxygenase pathway. In addition, the identified cellular targets could also serve 
as novel molecular targets for preventing or treating cancer and other human diseases. 
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Besides the EpFAs, their down-stream metabolites, termed fatty acid diols, have also 
been shown to be biologically active and could contribute to the biological actions of 
CYP monooxygenases and sEH. Recent studies have shown that dihydroxyeicosatrienoic 
acids (DHETs), which are metabolites of EETs produced by sEH, have pro-inflammatory 
effects 3,59. Treatment of 5,6-DHET, 8,9-DHET, 11,12-DHET, or 14,15-DHET at a dose 
of 3 µM stimulates primary human monocyte migration in vitro 50. Similar to the pro-
inflammatory effects of ARA-produced DHETs, recent studies show the DHA-produced 
dihydroxydocosapentaenoic acids (DHDPs) promote progression of retinopathy in mice 
60,61. Treatment of 19,20-DHDP induces retinal angiogenesis by increasing tip cell, 
sprouting, and filopodia numbers in mice, all of which contributes to proliferative 
retinopathy 60. Moreover, in an ex vivo whole mount retina model, treatment with 19,20-
DHDP increases vascular endothelial cell permeability and pericyte migration into 
extravascular space, both of which are disease markers for diabetic retinopathy 61. In 
cultured murine brain microvascular endothelial cells, treatment of 19,20-DHDP 
decreases junction formation between cells and reduces expression of N-cadherin, which 
could contribute to effect of  19,20-DHDP on vascular permeability during diabetic 
retinopathy 61. Overall, these studies demonstrate that fatty acid diols are bioactive 
eicosanoids which could contribute to the pathogenesis of many diseases. 
 
Together, these results support that CYP-produced eicosanoid metabolites, including 
EpOMEs, EETs, and EDPs, have potent effects on tumorigenesis. These results could 
help to establish a novel mechanistic linkage between fatty acid intake and cancer risks. 
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For example, animal experiments have shown that a high dietary intake of LA increases 
AOM-induced colon tumorigenesis, suggesting its potential adverse effect on CRC 62-66. 
Here our study about the promoting effects of LA-produced EpOMEs on CRC suggests 
that formation of EpOMEs contribute to promoting effects of LA on the risks of CRC 34. 
 
2.5 Roles of CYP eicosanoid pathway in obesity-induced colonic inflammation 
More than one-third of US adults (34.9% or 78.6 million) are obese 67, and obese 
individuals have 30-60% higher risk of developing CRC 13,68. Considering the obesity 
epidemic and the potential lethal consequence of CRC, obesity-enhanced CRC is a 
serious health problem in the US. However, the mechanism by which obesity increases 
the risks of CRC are not well understood, and there are few effective strategies to prevent 
obesity-enhanced CRC 14. Using LC-MS/MS-based metabolomics, our recent research 
suggests that sEH could be a novel therapeutic target of obesity-induced colonic 
inflammation 69. In a high fat diet (HFD)-induced obesity model in C57BL/6 mice, we 
find that the expression of sEH and the concentrations of sEH-produced fatty acid diols 
are significantly increased in the colon tissues of HFD-induced obese mice 69. 
Furthermore, genetic ablation of sEH abolishes HFD-induced colonic inflammation in 
mice, with reduced expression of pro-inflammatory cytokines 69. Furthermore, we find 
that the ablation of sEH attenuates HFD-induced activation of Wnt signaling pathway in 
colon tissues 69.  
 
Considering the critical roles of colonic inflammation and Wnt signaling in the 
pathogenesis of CRC, these results support that sEH could be a potential therapeutic 
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target of obesity-enhanced CRC. This notion is supported by previous studies, which 
show that inhibition of sEH has beneficial effects on colonic inflammation, CRC, and 
obesity, supporting that targeting sEH is a promising strategy to reduce the risks of 
obesity-enhanced CRC. Previous studies have shown that: (1) compared with normal 
colon tissues, the expression of sEH is increased in human CRC samples 31,35; (2) genetic 
ablation of sEH attenuates colonic inflammation and CRC 31-33; and (3) sEH is 
overexpressed in the liver and adipose tissues of obese mice 70,71. In addition, 
pharmacological inhibition or genetic ablation of sEH attenuated adverse consequences 
of obesity, including endoplasmic reticulum stress, metabolic syndrome, fatty liver, 
hepatic steatosis, inflammation, and endothelial dysfunction 16,38,39,70,72-76. Together, these 
results support that targeting sEH could be a promising strategy to reduce the risks of 
CRC in obese individuals. Further studies are needed to characterize the roles of sEH in 
obesity-enhanced CRC.  
 
In our studies, we find that the colonic expressions of CYP2C and CYP2J 
monooxygenases are not altered in HFD-treated mice 69. However, considering that the 
fatty acid diols are down-stream metabolites of CYP monooxygenases, it is feasible that 
inhibition of CYP monooxygenases could also reduce obesity-induced colonic 
inflammation and associated tumorigenesis. Targeting CYP monooxygenases could be an 
alternative approach to reduce the risks of obesity-enhanced CRC. This approach could 
minimize potential adverse effects of sEH inhibition on angiogenesis 28, and further 
studies are needed to better characterize the roles of the CYP eicosanoid pathway in 
obesity-enhanced CRC. 
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CHAPTER 3 
 
 LIPIDOMIC PROFILING OF HIGH-FAT DIET-INDUCED OBESITY IN MICE: 
IMPORTANCE OF CYTOCHROME P450-DERIVED FATTY ACID EPOXIDES  
 
3.1 Abstract 
Enzymatic metabolism of polyunsaturated fatty acids (PUFAs) leads to formation of 
bioactive lipid metabolites (LMs). Previous studies have shown that obesity leads to 
deregulation of LMs in adipose tissues. However, most previous studies have focused on 
single or limited number of LMs, few systematical analyses have been carried out. We 
used a LC-MS/MS-based lipidomics approach, which can analyze >100 LMs produced 
by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) enzymes, 
to analyze profile of LMs in high-fat diet-induced obesity in mice. LC-MS/MS showed 
that dietary feeding of high-fat diet significantly modulated profiles of LMs in adipose 
tissues. Among the three major PUFA metabolizing pathways (COX, LOX, and CYP), 
CYP-derived fatty acid epoxides were the most dramatically altered LMs. Almost all 
types of fatty acid epoxides were reduced by 70-90% in adipose tissues of high-fat diet-
fed mice. Consistent with the reduced levels of fatty acid epoxides, the gene expressions 
of several CYP monooxygenases, including Cyp2j5, Cyp2j6, and Cyp2c44, were 
significantly reduced in adipose tissues of high-fat diet-fed mice. Our results showed that 
CYP-derived fatty acid epoxides are the most responsive LMs in high-fat diet-induced 
obesity, suggesting that these LMs could play critical roles in obesity. 
 
3.2 Introduction 
Obesity is a major health concern in the US: more than one-third of US adults (34.9% or 
78.6 million) are obese 77. Obese individuals have significantly increased risks of 
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developing many diseases, including cardiovascular diseases, hypertension, type II 
diabetes, and certain types of cancer 78. The annual medical care cost to treat obesity and 
obesity-assocaited diseases is estimated to be around $190 billion in the US 79. Therefore, 
it is of critical importance to better understand the mechanism by which obesity increases 
the risks of various human diseases, which could facilitate the development of effective 
therapeutic strategies.  
 
The enzymatic metabolism of polyunsaturated fatty acids (PUFAs), such as arachidonic 
acid (ARA, 20:4ω-6), leads to formation of bioactive lipid metabolites (LMs), which are 
important lipid signaling molecules involved in regulation of many fundamental 
physiological and pathological processes 1-3. There are three major pathways involved in 
enzymatic metabolism of PUFAs: cyclooxygenase (COX-1 and COX-2), lipoxygenase 
(5-LOX, and 12/15-LOX), and cytochrome P450 (CYP). The COX pathway leads to 
formation of prostaglandins, which are important mediators to induce inflammation and 
pain; and COX-2 is the therapeutic target of many anti-inflammatory drugs on the market 
1. The LOX pathway produces leukotrienes and hydroxyl fatty acids, which are 
predominately pro-inflammatory and play critical roles in inflammatory diseases such as 
asthma 1. The CYP pathway converts PUFAs to fatty acid epoxides, which have a variety 
of beneficial effects such as anti-inflammatory, cardio-protective, vasodilative, and 
analgesic actions 2,3. Besides ARA, other PUFAs, including linoleic acid (LA, 18:2ω-6), 
α-linolenic acid (α-LA, 18:3ω-3), γ-linolenic acid (γ-LA, 18:3ω-6), dihomo-γ-linolenic 
acid (DGLA, 20:3ω-6), eicosapentaenoic acid (EPA, 20:5ω-3), and docosahexaenoic acid 
(DHA, 22:6ω-3), are also efficient alternative substrates of these enzymes and are 
 19 
converted to the corresponding LMs with unique biological activities 3-5. Together, this 
leads to formation of a large array of LMs with diverse chemical structures, many of 
which have potent biological activities. 
 
Previous research has shown that LMs play critical roles in pathology of obesity. In obese 
Zucker rats, there is attenuated production of prostacyclin (PGI2), which is a LM 
produced by COX enzymes with potent anti-inflammatory and vasodilative effects 80. 
Reduced levels of this beneficial LM could contribute to increased adipose inflammation 
and impaired adipose tissue blood flow (ATBF) in obesity. Dietary feeding of high-fat 
diet (HFD) increased tissue levels of LOX-derived leukotriene B4 (LTB4); and inhibition 
of LTB4 receptor protected mice from HFD-induced insulin resistance and hepatic 
steatosis 81, suggesting that LOX pathway contributes to increased risks of obesity-
associated diseases. Dietary feeding of HFD also reduced levels of CYP-derived 
epoxyeicosatrienoic acids (EETs), which have potent anti-inflammatory, vasodilative, 
and cardio-protective effects 16,82,83. Pharmacological inhibition or transgenic deletion of 
soluble epoxide hydrolase (sEH, the dominant enzyme in degrading EETs) have been 
shown to protect mice from various adverse effects induced by obesity 38,39,70,72-76. 
Together, these results support that LMs play critical roles in regulating the pathology of 
obesity.  
 
Most previous studies of LMs in obesity have only studied single or limited number of 
LMs 38,39,70,72-76,80,81. However, the enzymatic metabolism of PUFAs produces hundreds 
of LMs, which could have different or even opposite biological activities, it would be 
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difficult to understand the biological processes by only studying single or limited number 
of LMs 84. Therefore, it is important to conduct comprehensive profiling of a variety of 
LMs in tissues, which could help us to better understand their roles in pathology of 
obesity, in order to develop novel biomarkers or therapeutic targets for obesity and 
obesity-associated diseases. To this end, here we used a LC-MS/MS-based lipidomics 
approach, which can simultaneously measure the concentrations of > 100 LMs produced 
by COX (COX-1, COX-2), LOX (5-LOX, 12/15-LOX) and CYP enzymes from ARA, 
LA, α-LA , DGLA, EPA, and DHA 85,86 (see Table 3.1), to systematically analyze how 
lipid signaling is deregulated in obesity.   
 
3.3 Materials and Method 
3.3.1 Obesity experiment 
The animal experiment was conducted in accordance with the protocols approved by the 
Institutional Animal Care and Use Committee of UMass-Amherst. C57BL/6 male mice 
(6-week age) were maintained on a high-fat diet (60% kcal% fat, purchased from 
Research Diet Inc., catalog number D12492) and a control diet (10 kcal% fat, D12450J 
from Research Diet Inc.) for 8 weeks. 
 
3.3.2 LC-MS/MS-based lipidomics analysis 
To extract lipid metabolites from adipose tissues, ~100 mg tissues were mixed with an 
antioxidant solution (0.2 mg/mL butylated hydroxytoluene and 0.2 mg/mL 
triphenylphosphine in methanol), deuterated internal standards, and 400 μL extract 
solution (0.1% acetic acid with 0.2 mg/mL butylated hydroxytoluene in a methanol 
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solution), and then homogenized; the resulting homogenates were kept in −80 °C 
overnight. After centrifugation of the homogenates, the pellets were washed with 
methanol (containing 0.1% butylated hydroxytoluene and 0.1% acetic acid) and then 
combined with the supernatant. The lipid metabolites in the combined solutions were 
loaded onto pre-washed Waters® Oasis solid phase extraction (SPE) cartridges, washed 
with 95:5 water/methanol with 0.1% acetic acid, the analytes were eluted with methanol 
and ethyl acetate, dried using a centrifugal vacuum evaporator, then reconstituted in 
methanol for LC-MS/MS analysis. The LC-MS/MS analysis was carried out on an 
Agilent 1200SL HPLC system (Agilent, Santa Clara, CA) coupled to a 4000 QTRAP 
MS/MS (AB Sciex, Foster City, CA) as described in our previous report (24).  
 
3.3.3 Real-time PCR (RT-PCR) analysis 
Total RNA was isolated from gonadal adipose tissues using TRIzol Reagent (Life 
technologies, Carlsbad, CA) according to manufacturer’s instruction. Conversion of up to 
2 µg of total RNA to single stranded cDNA was preformed using High-Capacity cDNA 
Reverse Transcription Kit (Life technologies, Carlsbad, CA) according to manufacturer’s 
instruction. Quantitative RT-PCR was conducted using Maxima SYBR Green/ROX 
qPCR Master Mix (Thermo Fisher Scientific, Agawam, MA) on a DNA Engine 
Opticon® 2 System (Bio-Rad Laboratories, Hercules, CA) with specific mouse primers. 
The primers used in this research were: Cyp2j5 (sense) 5’-
TCTGGGAAGCACTCCATCTCA-3’ and (antisense) 5’-
CCCTGGTGGGTAGTTTTTGG-3’,  
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Cyp2j6 (sense) 5’-TTAGCCACGATCTGGGCAG-3’ and (antisense) 5’-
CTGGGGGATAGTTCTTGGGG-3’, Cyp2c44 (sense) 5’-
GCTGCCCTATACAGATGCCG-3’ and (antisense) 5’-
GTGACGCTAAGAGTTGCCCA-3’, Ephx2 (sense) 5’-GCGTTCGACCTTGACGGAG-
3’ and (antisense) 5’-TGTAGCTTTCATCCATGAGTGGT-3’,  
Alox15 (sense) 5’-GGCTCCAACAACGAGGTCTAC-3’ and (antisense) 5’-
AGGTATTCTGACACATCCACCTT-3’, Alox5 (sense) 5’-
ACTACATCTACCTCAGCCTCATT-3’ and (antisense) 5’-
GGTGACATCGTAGGAGTCCAC-3’, Cox2 (sense) 5’-
TTCAACACACTCTATCACTGGC-3’ and (antisense) 5’-
AGAAGCGTTTGCGGTACTCAT-3’, 
Pla2 (sense) 5’-TGCCTTTCCTGTAGGCTGTTC-3’ and (antisense) 5’-
CGCAGGTCTCGTAGCATCTG-3’, Ptges (sense) 5’-GGATGCGCTGAAACGTGGA-
3’ and (antisense) 5’-CAGGAATGAGTACACGAAGCC-3’, Ptgis (sense) 5’-
ACAGCATCAAACAATTTGTCGTC-3’ and (antisense) 5’-
GCATCAGACCGAAGCCATATCT-3’. 
The results of target genes were normalized to β-actin gene and expressed to the control 
group mice using the 2-ΔΔCt method. The primer to analyze β-actin is (sense) 5’-
GGCTGTATTCCCCTCCATCG-3’ and (antisense) 5’-
CCAGTTGGTAACAATGCCATGT-3’. 
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3.3.4 Fatty acid composition analysis 
Total lipids from gonadal adipose tissue were extracted as previously described (25), then 
treated with 3 N methanolic HCl at 55°C for 40 minutes to prepare the fatty acid methyl 
esters (FAMEs) (26). The resulted FAMEs dissolved in hexane were used for GC-MS 
analysis, using Shimadzu GC-MS-QP2010 SE (Tokyo, Japan). Oven conditions: initial 
temperature 50°C; temperature increase: 20°C/min to 200 °C, then increase 2°C/min to 
220°C and held for 142.5 minutes. Other conditions: injector temperature 250 oC; 
detector temperature 250 oC; carrier gas helium, split ratio: 10:1. Column: Supelcowax 
10 (fused silica), 100 m x 0.25 mm x 0.25 µm. The FAMEs were identified by comparing 
with the standards (Sigma-Aldrich, St. Louis, MO, or Nu-Chek Prep, Elysian, MN) or by 
their mass spectra, which were further compared to the NIST Mass Spectral library. 
 
3.3.5 Data Analysis 
All data are expressed as the mean ± standard error of the mean (SEM). For the 
comparison between the control group and HFD group, Shapiro-Wilk test was used to 
verify the normality of data. When data were normally distributed, statistical significance 
was determined using two-side t-test; otherwise, significance was determined by Mann-
Whitney U test. All of these data analysis was performed by using SigmaPlot software 
(San Jose, CA). P values less than 0.05 are reported as statistically significant. 
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Table 3.1 List of eicosanoid metabolites in LC-MS/MS method. 
 
Abbreviation Full Name Systematic Name 
6-keto-PGF1a 6-keto-Prostaglandin 
F1α 
6-oxo-9S,11R,15S-trihydroxy-13E-
prostenoic acid 
20-COOH-LTB4 12-oxo-10 (5R,6Z,8E,14Z)-5-hydroxy-12-oxoicosa-
6,8,14-trienedioic acid 
Resolvin E1 Resolvin E1 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-
eicosapentaenoic acid 
20-OH-LTB4 20-hydroxy LTB4 (5S,6Z,8E,10E,12R,14Z)-5,12,20-
trihydroxyicosa-6,8,10,14-tetraenoic acid 
TXB2 Thromboxane B2 9S,11,15S-trihydroxy-thromboxa-5Z,13E-
dien-1-oic acid 
PGE3 Prostaglandin E3 9-oxo-11R,15S-dihydroxy-5Z,13E,17Z-
prostatrienoic acid 
PGD3 Prostaglandin D3 9S,15S-dihydroxy-11-oxo-5Z,13E,17Z-
prostatrienoic acid 
9,12,13-TriHOME Pinellic acid 9S,12S,13S-trihydroxy-10E-octadecenoic 
acid 
9,10,13-TriHOME  9,10,13-trihydroxy-11-octadecenoic acid 
PGF2a Prostaglandin F2α 9S,11R,15S-trihydroxy-5Z,13E-prostadienoic 
acid 
PGE2 Prostaglandin E2 9-oxo-11R,15S-dihydroxy-5Z,13E-
prostadienoic acid 
PGE1 Prostaglandin E1 9-oxo-11R,15S-dihydroxy-13E-prostaenoic 
acid 
PGD1 Prostaglandin D1 9S,15S-dihydroxy-11-oxo-13E-prostaenoic 
acid 
PGD2 Prostaglandin D2 9S,15S-dihydroxy-11-oxo-5Z,13E-
prostadienoic acid 
LXA4 Lipoxin A4 5S,6R,15S-trihydroxy-7E,9E,11Z,13E-
eicosatetraenoic acid 
11,12-,15-
TriHETrE 
11,12,15-TriHETRE (8E,11Z,13E)-11,12,15-trihydroxyicosa-
8,11,13-trienoic acid 
LTB5 Leukotriene B5 5S,12S-dihydroxy-6Z,8E,14Z,17Z-
eicosapentanenoic acid 
PGJ2 Prostaglandin J2 11-oxo-15S-hydroxy-5Z,9,13E-prostatrienoic 
acid 
PGB2 Prostaglandin B2 15S-hydroxy-9-oxo-5Z,8(12),13E-
prostatrienoic acid 
15,16-DiHODE α-15,16-DiHODE (+/-)-15,16-dihydroxy-9Z,12Z-
octadecadienoic acid 
8,15-DiHETE 8,15-DiHETE (5Z,9E,11Z,13E)-8,15-dihydroxyicosa-
5,9,11,13-tetraenoic acid 
9,10-DiHODE α-9,10-DiHODE (+/-)-9,10-dihydroxy-12Z,15Z-
octadecadienoic acid 
12,13-DiHODE α-12,13-DiHODE (+/-)-12,13-dihydroxy-9Z,15Z-
octadecadienoic acid 
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6-trans-LTB4 6-trans-Leukotriene 
B4 
5S,12R-dihydroxy-6E,8E,10E,14Z-
eicosatetraenoic acid 
5,15-DiHETE 5,15-DiHETE (6E,8Z,11Z,13E)-5,15-dihydroxyicosa-
6,8,11,13-tetraenoic acid 
17,18-DiHETE 17,18-DiHETE (+/-)-17,18-dihydroxy-5Z,8Z,11Z,14Z-
eicosatetraenoic acid 
LTB4 Leukotriene B4 5S,12R-dihydroxy-6Z,8E,10E,14Z-
eicosatetraenoic acid 
14,15-DiHETE 14,15-DiHETE (+/-)-14,15-dihydroxy-5Z,8Z,11Z,17Z-
eicosatetraenoic acid 
11,12-DiHETE 11,12-DiHETE (+/-)-11,12-dihydroxy-5Z,8Z,14Z,17Z-
eicosatetraenoic acid 
12,13-DiHOME (9Z)-12,13-
Dihydroxyoctadec-9-
enoic acid 
12,13-dihydroxy-9Z-octadecenoic acid 
8,9-DiHETE 8,9-DiHETE (+/-)-8,9-dihydroxy-5Z,11Z,14Z,17Z-
eicosatetraenoic acid 
9,10-DiHOME Leukotoxin diol 9,10-dihydroxy-12Z-octadecenoic acid 
19,20-DiHDPE 19,20-DiHDPA (+/-)-19,20-dihydroxy-4Z,7Z,10Z,13Z,16Z-
docosapentaenoic acid 
14,15-DHET (+/-)14,15-DHET 14,15-dihydroxy-5Z,8Z,11Z-eicosatrienoic 
acid 
16,17-DiHDPE 16,17-DiHDPE (+/-)-16,17-dihydroxy-4Z,7Z,10Z,13Z,19Z-
docosapentaenoic acid 
11,12-DHET (+/-)11,12-DHET 11,12-dihydroxy-5Z,8Z,14Z-eicosatrienoic 
acid 
13,14-DiHDPE 13,14-DiHDPE (+/-)-13,14-dihydroxy-4Z,7Z,10Z,16Z,19Z-
docosapentaenoic acid 
9-HOTrE 9-HOTrE 9S-hydroxy-10E,12Z,15Z-octadecatrienoic 
acid 
10,11-DiHDPE 10,11-DiHDPE (+/-)-10,11-dihydroxy-4Z,7Z,13Z,16Z,19Z-
docosapentaenoic acid 
8,9-DHET (+/-)8,9-DHET 8,9-dihydroxy-5Z,11Z,14Z-eicosatrienoic 
acid 
EKODE trans-EKODE-(E)-Ib 9-oxo-11-(3-pentyloxiran-2-yl)undec-10-
enoic acid 
13-HOTrE 13-HoTrE 13S-hydroxy-9Z,11E,15Z-octadecatrienoic 
acid 
5,6-DiHETE 5S,6R-DiHETE 5S,6R-dihydroxy-7E,9E,11Z,14Z-
eicosatetraenoic acid 
15-deoxy-PGJ2 15-deoxy-δ-12,14-
Prostaglandin J2 
11-oxo-5Z,9,12E,14E-prostatetraenoic acid 
7,8-DiHDPE 7,8-DiHDPE (+/-)-7,8-dihydroxy-4Z,10Z,13Z,16Z,19Z-
docosapentaenoic acid 
20-HETE 20-hydroxy 
arachidonic acid 
20-hydroxy-5Z,8Z,11Z,14Z-eicosatetraenoic 
acid 
15-HEPE 15-HEPE (5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-
5,8,11,13,17-pentaenoic acid 
5,6-DHET (+/-)5,6-DHET 5,6-dihydroxy-8Z,11Z,14Z-eicosatrienoic 
acid 
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8-HEPE (+/-)-8-HEPE (+/-)-8-hydroxy-5Z,9E,11Z,14Z,17Z-
eicosapentaenoic acid 
12-HEPE (+/-)-12-HEPE (+/-)-12-hydroxy-5Z,8Z,10E,14Z,17Z-
eicosapentaenoic acid 
5-HEPE (+/-)-5-HEPE (+/-)-5-hydroxy-6E,8Z,11Z,14Z,17Z-
eicosapentaenoic acid 
4,5-DiHDPE 4,5-DiHDPE (+/-)-4,5-dihydroxy-4Z,7Z,13Z,16Z,19Z-
docosapentaenoic acid 
13-HODE 13S-HODE 13S-hydroxy-9Z,11E-octadecadienoic acid 
9-HODE 9-HODE 9-hydroxy-10E,12Z-octadecadienoic acid 
15,16-EpODE 15,16-EpODE 15,16-epoxy-13-OH-9Z,11E-octadecadienoic 
acid 
15-HETE 15-HETE 5-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic 
acid 
9,10-EpODE 9,10-EpODE 9S,10-epoxy-10,12Z-octadecadienoic acid 
17,18-EEQ 17,18-EpETE (+/-)-17(18)-epoxy-5Z,8Z,11Z,14Z-
eicosatetraenoic acid 
17-HDoHE (+/-)-17-HDoHE (+/-)-17-hydroxy-4Z,7Z,10Z,13Z,15E,19Z-
docosahexaenoic acid 
11-HETE 11-HETE 11-hydroxy-5Z,8Z,11E,14Z-eicosatetraenoic 
acid 
12,13-EpODE α-12(13)-EpODE 12(13)-epoxy-9Z,15Z-octadecadienoic acid 
13-oxo-ODE 13-KODE 13-keto-9Z,11E-octadecadienoic acid 
15-oxo-ETE 15-Oxo-ETE 15-oxo-5Z,8Z,11Z,13E-eicosatetraenoic acid 
9-oxo-ODE 9-OxoODE 9-oxo-10,12-octadecadienoic acid 
14,15-EEQ 14(15)-EpETE (+/-)-14(15)-epoxy-5Z,8Z,11Z,17Z-
eicosatetraenoic acid 
8-HETE 8-HETE 8-hydroxy-5Z,9E,11Z,14Z-eicosatetraenoic 
acid 
12-HETE 12-HETE 12-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic 
acid 
11,12-EEQ 11(12)-EpETE (+/-)-11(12)-epoxy-5Z,8Z,14Z,17Z-
eicosatetraenoic acid 
8,9-EEQ 8(9)-EpETE (+/-)-8(9)-epoxy-5Z,11Z,14Z,17Z-
eicosatetraenoic acid 
9-HETE 9-HETE 9-hydroxy-5Z,7E,11Z,14Z-eicosatetraenoic 
acid 
15(S)-HETrE 15S-HETrE 15S-hydroxy-8Z,11Z,13E-eicosatrienoic acid 
12-oxo-ETE 12-oxo-ETE 12-oxo-5Z,8Z,10E,14Z-eicosatetraenoic acid 
5-HETE 5-HETE 5-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic 
acid 
19,20-EDP 19,20-EpDPE (+/-)-19(20)-epoxy-4Z,7Z,10Z,13Z,16Z-
docosapentaenoic acid 
12,13-EpOME Vernolic acid (+/-)-12(13)-epoxy-9Z-octadecenoic acid 
14,15-EET 14,15-EpETrE 14,15-epoxy-5Z,8Z,11Z-eicosatrienoic acid 
9,10-EpOME Coronaric acid 9,10-epoxy-12Z-octadecenoic acid 
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16,17-EDP 16(17)-EpDPE (+/-)-16(17)-epoxy-4Z,7Z,10Z,13Z,19Z-
docosapentaenoic acid 
13,14-EDP 13(14)-EpDPE (+/-)-13(14)-epoxy-4Z,7Z,10Z,16Z,19Z-
docosapentaenoic acid 
5-oxo-ETE 5-Oxo-ETE 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid 
10,11-EDP 10(11)-EpDPE (+/-)-10(11)-epoxy-4Z,7Z,13Z,16Z,19Z-
docosapentaenoic acid 
11,12-EET 11,12-EpETrE 11,12-epoxy-5Z,8Z,14Z-eicosatrienoic acid 
7,8-EDP 7(8)-EpDPE (+/-)-7(8)-epoxy-4Z,10Z,13Z,16Z,19Z-
docosapentaenoic acid 
8,9-EET 8,9-EpETrE 8,9-epoxy-5Z,11Z,14Z-eicosatrienoic acid 
5,6-EET 5,6-EpETrE 5,6-epoxy-8Z,11Z,14Z-eicosatrienoic acid 
 
3.4 Results 
3.4.1 CYP-derived LMs in adipose tissues 
After 8 weeks of dietary feeding, HFD significantly increased body weight and adipose 
tissue weight in C57BL/6 mice (Figure 3.1). These results are consistent with previous 
studies of HFD on obesity 87.  
 
Figure 3.1 Dietary feeding of HFD for 8 weeks increased body weight and adipose 
tissue weight in C57BL/6 mice. 
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We used LC-MS/MS-based lipidomics to compare the profiles of LMs in inguinal, 
gonadal, and interscapular adipose tissues of mice fed on HFD or control diet. Among the 
three major PUFA metabolizing pathways (COX, LOX, and CYP), CYP-derived fatty 
acid epoxides are the most dramatically altered LMs in adipose tissues. The levels of 
fatty acid epoxides derived from several PUFAs, including epoxyoctadecenoic acids 
(EpOMEs) derived from LA, EETs from ARA, epoxydocosapentaenoic acids (EpDPEs) 
from DHA, and epoxyoctadecadienoic acids (EpODEs) from α-LA, were significantly 
reduced in different adipose tissues (inguinal, gonadal, and interscapular fats) of HFD-fed 
mice (Figure 3.2A-C). For example, the concentrations of 11,12-EET and 14,15-EET 
were reduced by respective 88±20% and 89±18% in inguinal adipose tissues (P ≤ 0.001), 
and were reduced by respective 88±13% and 89±11% in gonadal fat tissues of HFD-fed 
mice (P ≤ 0.001).  
 
The fatty acid epoxides are further metabolized by soluble epoxide hydrolase (sEH) to 
generate the corresponding fatty acid diols 81. Consistent with reduced adipose levels of 
fatty acid epoxides, the levels of fatty acid diols were also significantly reduced (Figure 
3.2A-C). For example, the levels of 11,12-dihydroxyeicosatrienoic acid (11,12-DHET), 
which is a sEH metabolite of 11,12-EET, were reduced by 54.5±10.7% (mean ± SEM) in 
gonadal adipose tissues of HFD-fed mice (P ≤ 0.001). We need to point out in the adipose 
tissues, the concentrations of fatty acid epoxides were much higher than those of the 
corresponding fatty acid diols. For example, the concentration of 11,12-EET was ~73-
fold higher than its sEH metabolite 11,12-DHET in gonadal adipose tissues of control 
mice.  
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 Figure 3.2 Dietary feeding of HFD reduces levels of CYP-derived fatty acid epoxides 
and fatty acid diols in adipose tissues. 
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(A) profiles of CYP-derived LMs in inguinal adipose tissues. (B) profiles of CYP-derived 
LMs in gonadal adipose tissues. (C) profiles of CYP-derived LMs in interscapular 
adipose tissues. 
 
3.4.2 COX-derived LMs in adipose tissues 
The metabolism of PUFAs by COX enzymes lead to formation of prostaglandin H2 
(PGH2), which was further enzymatically metabolized to generate various prostaglandins 
(Figure 3.3A). Compared with CYP-derived LMs, the profiles of COX-derived LMs 
showed more complicated patterns. In inguinal adipose tissues, the levels of COX-
derived LMs were not changed (Figure 3.3B), suggesting that COX pathway is not likely 
to be involved in the biology of inguinal adipose tissues. In gonadal adipose tissues, the 
concentrations of PGI2 (as measured by its stable metabolite 6-keto-PGF1a) and PGE2 
were significantly reduced in HFD-fed mice (Figure 3.3C). In interscapular adipose 
tissues, the concentrations of PGF2α and PGE2 were significantly reduced in HFD-fed 
mice (P < 0.05, Figure 3.3D). 
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Figure 3.3 Dietary feeding of HFD modulates COX-derived LMs in adipose tissues. 
(A) a simplified sheme of COX-2 pathway. (B) profiles of COX-derived LMs in inguinal 
adipose tissues. (C) profiles of COX-derived LMs in gonadal adipose tissues. (D) profiles 
of COX-derived LMs in interscapular adipose tissues.  
 
3.4.3 5-LOX-derived LMs in adipose tissues 
The metabolism of ARA by 5-LOX leads to formation of 5-hydroperoxyeicosatetraenoic 
acid (5-HpETE), which is then converted to at least two classes of LMs: (1) 5-
hydroxyeicosatetraenoic acid (5-HETE), or similar LMs such as α-LA-derived 9-HOTrE 
and EPA-derived 5-HEPE, and (2) LTB4, or similar LMs such as EPA-derived 
leukotriene B5 (LTB5) (Figure 3.4A). Dietary feeding of HFD reduced levels of 5-HETE-
series LMs (such as 5-HETE, 9-HOTrE, and 5-HEPE), while increased levels of LTB4 in 
adipose tissues (Figure 3.4B-D). The tissue levels of LTB4 were significantly increased in 
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inguinal, gonadal, interscapular adipose tissues of HFD-fed mice (Figure 3.4B-D), which 
is in agreement with studies which showed that HFD increased tissue levels of LTB4 81. 
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Figure 3.4 Dietary feeding of HFD modulates 5-LOX-derived LMs in adipose 
tissues. 
(A) a simplified sheme of 5-LOX pathway. (B) profiles of 5-LOX-derived LMs in 
inguinal adipose tissues. (C) profiles of 5-LOX-derived LMs in gonadal adipose tissues. 
(D) profiles of 5-LOX-derived LMs in interscapular adipose tissues. 
 
3.4.4 12/15-LOX-derived LMs in adipose tissues 
The metabolism of PUFAs by 12/15-LOX leads to formation of a series of LMs (Figure 
3.5A). LC-MS/MS showed that many of these LMs were reduced in adipose tissues of 
HFD-fed mice (Figure 3.5B-D). For example, the tissue levels of 15-HETE were 
significantly reduced in inguinal, gonadal, and interscapular adipose tissues of HFD-fed 
mice (Figure 3.5B-D). 12-HETE, which is among the most abundant LOX-derived LMs 
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in adipose tissues, was reduced by 71.7±6.78% (mean ± SEM) in interscapular adipose 
tissue of HFD-fed mice (Figure 3.5D).  
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Figure 3.5 Dietary feeding of HFD modulates 12/15-LOX-derived LMs in adipose 
tissues. 
(A) a simplified sheme of 12/15-LOX pathway. (B) profiles of 12/15-LOX-derived LMs 
in inguinal adipose tissues. (C) profiles of 12/15-LOX-derived LMs in gonadal adipose 
tissues. (D) profiles of 12/15-LOX-derived LMs in interscapular adipose tissues. 
 
3.4.5 Fatty acid composition and expression of COX, LOX and CYP in adipose 
tissues 
The tissue profiles of LMs are in part mediated by fatty acid composition and expression 
of PUFA metabolizing enzymes in the tissues 3. To understand the mechanisms by which 
HFD modulated LMs in adipose tissues, we analyzed fatty acid composition and gene 
expression of COX, LOX and CYP in adipose tissues. We focused on gonadal adipose 
tissues, which are the largest adipose tissues, since we have observed significant changes 
of most LMs in gonadal fat (Figure 3.1-3.5).    
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For fatty acid composition, as expected, triglycerides were major lipids in the gonadal 
adipose tissue, with minimum amount of phospholipids (determined by TLC method 
based on Ref 88, data not shown), which is consistent to previous studies 89. Therefore, we 
analyzed fatty acid composition from the total lipid of adipose tissues. GC-MS analysis 
showed that dietary feeding of HFD did not change the tissue levels of ARA and α-LA, 
and slightly increased tissue levels of LA (22.50±0.18% in HFD group vs. 17.78±0.44% 
in control group, P < 0.001). These results support that dietary feeding of HFD did not 
reduce levels of PUFAs in adipose tissues, suggesting that the reduced levels of many 
LMs in adipose tissues were not due to lack of PUFA substrates.  
 
For gene expressions of PUFA metabolizing enzymes, RT-PCR showed that the 
expressions of several CYP monooxygenases, such as Cyp2j5, Cyp2j6, and Cyp2c44, 
were significantly reduced in the gonadal adipose tissues of HFD-fed mice (Figure 3.6A), 
which is well consistent with the reduced levels of CYP-derived fatty acid epoxides in 
adipose tissues (see Figure 3.6B). The expression of Ephx2 (encoding sEH) was not 
changed (Figure 3.6A). For COX pathway, the gene expression of Cox2 was not changed, 
while the expressions of Ptges (encoding microsomal prostaglandin E synthase) and Ptgis 
(encoding PGI2 synthase) were significantly reduced in HFD-fed mice (Figure 3.6B). 
This is consistent with the LC-MS/MS analysis which showed that only PGE2 and PGI2, 
but not other COX-derived LMs, were reduced in adipose tissues of HFD-fed mice. For 
LOX pathways, the gene expressions of Alox15 and Alox5 (encoding 5-LOX) were not 
significantly changed (Figure 3.6C), suggesting that the effects of HFD on LOX-derived 
LMs may be though modulations of down-stream enzymes. Finally, we analyzed the 
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expression of Pla2, and found little change of this gene (Figure 3.6C). Together, these 
results support that HFD changed tissue profiles of LMs mainly through modulation of 
the expressions of PUFA metabolizing enzymes in adipose tissues. 
 
Figure 3.6 Effect of HFD on gene expresions of PUFA metabolizing enzymes in 
gonadal adipose tissues.  
(A) gene expressions of enzymes involved in CYP pathway. (B) gene expressions of 
enzymes in COX pathway. (C) gene expressions of enzymes in LOX pathway, as well as 
phospholipase A2 (PLA2). 
 
 36 
3.5 Discussion 
In this study, we conducted a LC-MS/MS-based lipidomics analysis of HFD-induced 
obesity in mice. Our central finding is that HFD significantly modulated the profiles of 
LMs in adipose tissues of mice. Among the three major PUFA metabolizing pathways 
(COX, LOX and CYP), CYP-derived fatty acid epoxides are the most dramatically 
changed LMs in adipose tissues of HFD-induced obesity. Almost all types of fatty acid 
epoxides, including EpOMEs derived from LA, EETs from ARA, EpDPEs from DHA, 
and EpODEs from α-LA, were reduced by 70-90% in different types of adipose tissues. 
Based on our GC-MS analysis of fatty acid composition and RT-PCR analysis of PUFA 
metabolizing enzymes, these changes were most likely caused by reduced expressions of 
CYP monooxygenases, not because the PUFA substrates were reduced in adipose tissues 
of HFD-fed mice. Our results are consistent with previous studies, which showed that 
EETs are reduced in adipose tissues of HFD-fed mice 16. Many of these fatty acid 
epoxides have beneficial effects on health. ARA-derived EETs have been shown to have 
potent anti-inflammatory, vasodilative, anti-hypertensive, cardio-protective, renal-
protective, and analgesic actions 90. DHA-derived EpDPEs have been shown to be the 
most potent fatty acid epoxides in dilation of blood vessels, with EC50 values of 0.5- 24 
pM for dilation of porcine coronary arterioles 91. Our own study has shown that EDPs 
have potent anti-angiogenic, anti-cancer and anti-metastatic effects in vitro and in vivo 51. 
Therefore, reduced levels of these beneficial LMs, in particular EETs and EDPs, may 
contribute to the adverse effects of obesity. This is supported by recent studies, which 
showed that pharmacological inhibition or transgenic deletion of sEH, which is the 
dominant enzyme in degrading fatty acid epoxides, protected mice form various adverse 
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consequences of obesity, such as endoplasmic reticulum stress, metabolic syndrome, 
hepatic steatosis, inflammation, and endothelial dysfunction 16,38,39,70,72-76. Together, these 
results strongly support that CYP-derived fatty acid epoxides play important roles in 
regulating pathology of obesity.  
 
The profiles of COX- and LOX-derived LMs showed more complicated pattern in 
adipose tissues of HFD-induced obesity. For COX pathway, the relative balance of 
vasodilative PGI2 (as measured by its stable metabolite 6-keto-PGF1a) and 
vasoconstrictive TXA2 (as measured by its stable metabolite TXB2) plays critical role in 
regulating vascular tone and cardiovascular functions 1,92. Our study showed that dietary 
feeding of HFD reduced adipose levels of vasodilative PGI2, while had little effect on 
vasoconstrictive TXA2. These results support that PGI2 pathway, but not TXA2 pathway, 
may contribute to some adverse effects of obesity. Our results are consistent with 
previous studies which showed that biosynthesis of PGI2, but not TXA2, was attenuated in 
obese Zucker rats 80. We also found that the tissue levels of PGE2 were significantly 
reduced in obese mice. This is consistent with previous studies of HFD on adipose tissue 
levels of PGE2 93-96. The biological significance of PGE2 remains to be determined. On 
one hand, PGE2 is a potent vasodilator, reduced level of PGE2 could contribute to 
reduced ATBF of obesity 1; on the other hand, PGE2 is a potent inducer of inflammation 
1, reduced level of PGE2 is not consistent with the enhanced adipose inflammation in 
obesity. Previous studies have shown that HFD induced a dynamic change of adipose 
level of PGE2: in the early stage of HFD feeding (day 4 post HFD feeding), PGE2 was 
increased in adipose tissues; while at a later stage (day 14), its concentration was reduced 
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in adipose tissues 94. These results support that there may be a highly time-dependent 
change of tissue levels of LMs, in order to respond to varied cellular stimulations at 
different stages of obesity development.  
 
For LOX pathway, only the concentration of 5-LOX-derived LTB4 was significantly 
increased in adipose tissues. This is consistent with recent studies which showed that 
HFD increased tissue levels of LTB4; in addition, inhibition of LTB4 receptor protected 
mice from HFD-induced insulin resistance and hepatic steatosis 81, supporting a critical 
role of LTB4 in pathology of obesity. For 12/15-LOX pathway, our results showed that 
the many 12/15-LOX-derived LMs (12-HETE, 15-HETE, 15(s)-HETrE, and 13-HOTrE) 
were reduced in adipose tissues of HFD-fed mice. Our results are consistent with 
previous studies which showed that HFD reduced adipose concentrations of 12-HETE 
and 15-HETE 96. Some previous studies have shown that 12/15-LOX pathway is 
activated in obesity 97; and these different results could be because different animal 
models of obesity are used. Many of the LOX-derived hydroxyl fatty acids and 
leukotrienes have potent effects to regulate inflammation and vascular tone 1. It remains 
to determine whether reduced levels of 12/15-LOX-derived LMs contributed to adverse 
effects of obesity.    
 
In conclusion, our lipidomics analysis showed that HFD significantly modulated the 
profiles of LMs in adipose tissues of mice. In particular, CYP-derived fatty acid epoxides 
are the most dramatically altered LMs in HFD-induced obesity, suggesting that these 
novel LMs could play critical roles in pathology of obesity. This lipidomics study lays 
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the foundation to further investigate the functional roles of LMs in obesity, which could 
facilitate the development of novel biomarkers or therapeutic targets for obesity and 
obesity-associated diseases. 
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CHAPTER 4 
 
 TARGETED METABOLOMICS IDENTIFIES CYTOCHROME P450 
MONOOXYGENASE EICOSANOID PATHWAY AS NOVEL THERAPEUTIC 
TARGET OF COLON TUMORIGENESIS 
 
4.1 Abstract 
Colon cancer is the third most common cancer and the second leading cause of cancer-
related death in the United States, emphasizing the need for discovery of novel cellular 
targets which are crucial in the pathogenesis of colon cancer. Using a metabolomics 
approach, we find that epoxygenated fatty acids (EpFAs), which are eicosanoid 
metabolites produced by cytochrome P450 (CYP) monooxygenases, are increased in both 
the plasma and colon of azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced 
colon cancer mice. We further find that CYP monooxygenases are overexpressed in 
colon tumor tissues and colon cancer cells. Pharmacological inhibition or genetic ablation 
of CYP monooxygenases suppresses AOM/DSS-induced colon tumorigenesis in vivo. In 
addition, treatment with 12,13- epoxyoctadecenoic acid (EpOME), which is a metabolite 
of CYP monooxygenase produced from linoleic acid, increases cytokine production and 
JNK phosphorylation in vitro, and exacerbates AOM/DSS-induced colon tumorigenesis 
in vivo. Together, these results demonstrate that the previously unappreciated CYP 
monooxygenase pathway is upregulated in colon cancer, contributes to its pathogenesis, 
and could be therapeutically explored for preventing or treating colon cancer. 
 
4.2 Introduction 
Colon cancer is the third most common cancer and the second leading cause of cancer-
related death in the United States 6. It is important to discover novel cellular targets which 
are crucial in the pathogenesis of colon cancer, which could facilitate development of 
 41 
mechanism-based strategies to reduce the risks of colon cancer. Eicosanoids, which are 
endogenous lipid signaling molecules produced from enzymatic metabolism of 
arachidonic acid (ARA, 20:4ω-6), play essential roles in inflammation and have recently 
been implicated in cancer 18,19. There are three major pathways involved in biosynthesis 
of eicosanoids: cyclooxygenases (COX) producing prostaglandins and thromboxanes, 
lipoxygenases (LOX) producing leukotrienes and hydroxyl fatty acids, and cytochrome 
P450 (CYP) monooxygenases producing epoxygenated fatty acids (EpFAs) 1,3. Besides 
ARA, other polyunsaturated fatty acids, such as linoleic acid (LA, 18:2ω-6), α-linolenic 
acid (ALA, 18:3ω-3), and docosahexaenoic acid (DHA, 22:6ω-3), are also efficient 
alternative substrates for these metabolizing enzymes, which convert them to the 
corresponding fatty acid metabolites 1,3. As a result, the enzymatic metabolism of 
polyunsaturated fatty acids leads to formation of a large array of eicosanoid metabolites, 
many of which act as autocrine or paracrine mediators to regulate inflammation and 
hemostasis 1,3.  
 
Previous research has shown that certain eicosanoid metabolites are deregulated in colon 
cancer and contribute to its pathogenesis 23. Notably, the most prominent cancer-
associated eicosanoids are prostaglandins, which are produced by COX-2 that is 
overexpressed in most human colon cancer samples 19. Clinical and epidemiological 
studies support that pharmacological inhibitors of COX-2 are highly effective for 
preventing colon cancer 19, however, the gastrointestinal and cardiovascular toxicities 
induced by COX-2 inhibitors have limited their clinical applications 22,98. Besides COX-
2, the roles of other eicosanoid pathways in colon tumorigenesis are not well understood 
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23. It is important to discover novel eicosanoid signaling pathways involved in colon 
tumorigenesis. 
 
Most previous studies to investigate the roles of eicosanoids in colon tumorigenesis have 
only studied single or limited number of eicosanoid metabolite(s), few systematic 
analyses have been carried out, hampering our understanding of the roles of eicosanoid 
signaling in colon tumorigenesis 23. To discover novel eicosanoid metabolites and 
pathways involved in colon tumorigenesis, in this study we use a liquid chromatography 
tandem-mass spectrometry (LC-MS/MS)-based targeted metabolomics to systematically 
profile eicosanoids in a well-stablished azoxymethane (AOM)/dextran sulfate sodium 
(DSS)-induced colon cancer model in C57BL/6 mice, then use pharmacological and 
genetic approaches to validate the functional roles of identified metabolite in colon 
tumorigenesis. 
 
4.3 Materials and Method 
4.3.1 Animal experiment  
The animal experiments were conducted in accordance with the protocols approved by 
the Institutional Animal Care and Use Committee of the University of Massachusetts 
Amherst (protocol number: 2017-0019) and National Institutes of Health/National 
Institute of Environmental Health Sciences (protocol number: 05-18). 
 
Animal Protocol 1: AOM/DSS-induced colon tumorigenesis in mice 
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C57BL/6 male mice (age = 6 weeks) were purchased from Charles River and maintained 
on a modified AIN-93G diet (containing 10% fat, corn oil was the only source of fat 
content, diet composition was described in Table 4.1) for 3 weeks, then the mice were 
divided into two groups: (1) the mice in the AOM/DSS group were treated with 10 mg/kg 
AOM (Sigma-Aldrich) via intraperitoneal injection, at week 1 post the AOM injection, 
they were given 2% DSS (36–50 kDa, MP Biomedicals) in drinking water for 1 week; 
and (2) the mice in control group were maintained on the same diet without AOM/DSS 
treatment. At week 9.5 post the AOM injection, the mice were sacrificed to harvest 
plasma and colon tissues for analysis. For analysis of colon tumor, colon tissues were cut 
open longitudinally, washed in PBS and inspected under a dissection microscope. The 
size of the tumor was determined by the following formula: tumor size = π×d2/4, where d 
is the diameter of each tumor.  
 
Animal Protocol 2: AOM/DSS-induced colon tumorigenesis in Cyp2c+/+, Cyp2c+/- and 
Cyp2c-/-mice    
Littermate wildtype Cyp2c+/+ mice, heterozygous Cyp2c+/- mice and knockout Cyp2c-/- 
mice (background on C57BL/6, age = 6 weeks) were treated with 10 mg/kg AOM via i.p. 
injection. At week 1 post the AOM injection, they were given 2% DSS in drinking water 
for 1 week. During the whole experiment, the mice were maintained on mouse chow. At 
week 9.5 post the AOM injection, the mice were sacrificed to collect blood and colon 
tissues for analysis. 
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Animal Protocol 3: Effects of 12,13-epoxyoctadecenoic acid (EpOME) on 
AOM/DSS-induced colon tumorigenesis  
C57BL/6 male mice (age = 6 weeks) were treated with 10 mg/kg AOM via i.p. injection. 
At week 1 post the AOM injection, they were given 2% DSS in drinking water for 1 
week. At week 5 post the AOM injection, the mice were subcutaneously implanted with 
osmotic mini-pumps (Durect), which contained 12,13-EpOME (Cayman, dose of 12,13-
EpOME = 2 mg/kg/day) or vehicle (a 1:1 vol/vol mixed solution of DMSO and PEG 
400). During the whole experiment, the mice were maintained on mouse chow. At week 
9 post the AOM injection, the mice were sacrificed to collect blood and colon tissues for 
analysis.  
 
Animal Protocol 4: Effects of CYP inhibitors (SKF-525A and clotrimazole) on 
AOM/DSS-induced colon tumorigenesis in mice 
C57BL/6 male mice (age = 6 weeks, maintained on mouse chow) were treated with 
10 mg/kg AOM via i.p. injection. At week 1 post the AOM injection, they were given 2% 
DSS in drinking water for 1 week. After the AOM/DSS stimulation, the mouse diet was 
changed to a modified AIN-93G diet containing 200 ppm SKF-525A or clotrimazole 
(Alfa Aesar) dissolved in polyethylene glycol 400 (PEG 400, Millipore) as vehicle (0.1% 
in diet, v/w), or vehicle alone for 6 weeks. The diets were freshly prepared and changed 
every 2-3 days. At week 8 post the AOM injection, the mice were sacrificed to collect 
blood and colon tissues for analysis. 
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4.3.2 Statistical analysis 
Data are expressed as means ± SEM. Shapiro–Wilk test was used to verify the normality 
of data and Levene's mean test was used to assess equal variance of data. Statistical 
comparison of two groups was performed using either Student’s t test or Wilcoxon-
Mann-Whitney test (when normality test is failed), comparison of three groups was 
analyzed by either parametric one-way ANOVA or nonparametric one-way ANOVA 
(Kruskal–Wallis test by ranks, used when normality test is failed) followed by Dunn’s 
post hoc test. All of these data analysis was performed by using SigmaPlot software 
(Systat Software, Inc). P values less than 0.05 are reported as statistically significant. 
 
 
 
 
Table 4.1 Composition of the modified AIN-93G diet used in the animal experiment 
 
Ingredients grams/kg 
Casein 200 
L-Cystine 3 
Sucrose 100 
Dyetrose 132 
Cornstarch 397.5 
Cellulose 50 
Mineral mix #210025 35 
Vitamin mix #310025 10 
Choline Bitartrate 2.5 
Corn oil 100 
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4.4 Results 
4.4.1 CYP monooxygenase-produced eicosanoid metabolites are elevated in the 
plasma and colon of AOM/DSS-induced colon cancer mice 
To our knowledge, a metabolomics-based approach to systematically profile eicosanoids 
in colon cancer has not been attempted 23. In an effort to better understand the roles of 
eicosanoids in colon tumorigenesis, we used a LC-MS/MS-based targeted metabolomics 
to compare the profiles of eicosanoids in the plasma and colon of control healthy mice 
(not treated with AOM/DSS) and colon cancer mice (treated with AOM/DSS) (Figure 
4.1A). In agreement with previous studies of the AOM/DSS model 99, 100% of the 
AOM/DSS-treated mice developed colon tumors (Figure 4.1B), with increased 
expressions of pro-inflammatory genes (Il-6, Tnf-α, Mcp-1, and Cox-2) in the colon 
tissues (Figure 4.1C). 
 
LC-MS/MS detected 42 metabolites in the plasma and 56 metabolites in the colon. 
Among the detected metabolites, only CYP monooxygenase-produced EpFAs are 
significantly increased in both the plasma and colon tissues of the AOM/DSS-induced 
colon cancer mice (Figure 4.1D-G). Indeed, the concentrations of an array of EpFAs, 
including 9,10- and 12,13-epoxyoctadecenoic acid (EpOME) produced from LA (Figure 
4.1D), 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EET) from ARA (Figure 4.1E), 
9,10- and 15,16-epoxyoctadecadienoic acid (EpODE) from ALA (Figure 4.1F), and 
19,20-epoxydocosapentaenoic acid (EDP) from DHA (Figure 4.1G), are increased in the 
plasma and colon of the tumor-bearing mice.  
 
 47 
4.4.2 CYP monooxygenases are overexpressed in the colon of AOM/DSS-induced 
colon cancer mice 
To understand the underlying mechanisms behind elevated concentrations of EpFAs in 
colon cancer, we studied the expression of enzymes involved in EpFA production and 
removal. The biosynthesis and degradation of EpFAs involves three enzymatic steps: 
membrane-bound fatty acids are released by phospholipase A2 (PLA2) and related 
enzymes to generate intracellular free-form fatty acids, which are then metabolized by 
CYP monooxygenases (predominately CYP2C isoforms) to form EpFAs, which then 
undergo degradation by soluble epoxide hydrolase (sEH) 2,3. qRT-PCR showed that the 
expression of Pla2g4a (encoding cytosolic calcium-dependent PLA2) was unchanged, the 
expression of several CYP monooxygenases (including mouse Cyp2c38, Cyp2c39, 
Cyp2c65, and Cyp2c70) was increased (P < 0.05), and the expression of Ephx2 (encoding 
sEH) was decreased (P < 0.05), in colon tissue of mice with colon cancer (Figure 4.1H). 
Together, these results support that there is enhanced biosynthesis and reduced 
degradation of EpFAs in colon tumors of mice, which contributes to elevated EpFAs in 
colon cancer. 
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          H  
 
 
 
 
 
 
 
 
Figure 4.1 CYP monooxygenase-produced eicosanoid metabolites are increased in 
the plasma and colon of AOM/DSS-induced colon cancer mice.  
(A) Scheme of animal experiment. (B) Quantification of colon tumor in mice. (C) Gene 
expression of Tnf-α, Mcp-1, Il-6 and Cox-2 in colon. (D-G) Concentrations of CYP 
monooxygenase-produced EpFAs in plasma and colon. (H) Expression of Pla2, Cyp 
monooxygenases, and Ephx2 (encoding sEH) in colon.  
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4.4.3 CYP monooxygenases are overexpressed in human colon cancer cells 
To further validate that CYP monooxygenases are overexpressed in colon cancer, we 
studied their expressions in human colon cancer cells. Compared with normal human 
colon cells (CCD-18Co), the gene expression of CYP monooxygenases (human CYP2C8, 
2C9, 2C19, and 2J2) was significantly (P < 0.05) increased in human colon cancer cells 
(HCT116 and Caco-2) (Figure 4.2A). Consistent with the qRT-PCR result, 
immunoblotting showed that the protein expression of CYP monooxygenase (using 
human CYP2C9 as a marker) was increased in human colon cancer cells (Figure 4.2B). 
These results demonstrate that the CYP monooxygenases are overexpressed in human 
colon cancer cells, which is consistent with the results from animal experiments. 
 
Figure 4.2 CYP monooxygenases are overexpressed in human colon cancer cells.  
(A) Gene expression of CYP monooxygenases (human CYP2C8, CYP2C9, CYP2C19, 
and CYP2J2) in normal human colon cells (CCD-18Co) and human colon cancer cells 
(HCT-116 and Caco-2). (B) Western blotting analysis of CYP2C9 expression in normal 
colon cells and colon cancer cells.  
 
4.4.4 Genetic ablation of CYP monooxygenases suppresses AOM/DSS-induced colon 
tumorigenesis 
To determine the roles of CYP monooxygenases in colon cancer, we tested whether 
genetic ablation of CYP monooxygenases modulates colon tumorigenesis. To this end, 
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we performed the AOM/DSS-induced colon cancer model in a recently developed Cyp2c 
gene cluster knockout mouse, which has deletions of fourteen mouse Cyp2c genes, 
including Cyp2c29, 2c37, 2c38, 2c39, 2c40, 2c50, 2c54, 2c55, 2c65, 2c66, 2c67, 2c68, 
2c69, and 2c70 100 (Figure 4.3A). Compared with Cyp2c+/+ mice, the expression of 
Cyp2e1 (encoding the enzyme Cyp2e1 to activate the mutagenic activity of AOM 101) 
was not changed in Cyp2c+/- or Cyp2c-/- mice, supporting that it is feasible to perform the 
AOM/DSS-induced colon tumorigenesis model in these mice. 
 
Compared with AOM/DSS-induced Cyp2c+/+ mice, the AOM/DSS-induced Cyp2c+/- 
mice had lower tumor number and total tumor burden (Figure 4.3B), reduced expression 
of tumorigenic markers proliferating cell nuclear antigen (PCNA) and β-catenin (Figure 
4.3C), and attenuated expression of pro-inflammatory and pro-tumorigenic genes (Tnf-α, 
Il-1β, Axin2 and C-myc), in the colon tumor tissue (Figure 4.3D), illustrating reduced 
colon tumorigenesis. In addition, we found that compared with AOM/DSS-induced 
Cyp2c+/+ mice, the colon of AOM/DSS-induced Cyp2c+/- mice had lower colonic 
expression of Cyp monooxygenase (using mouse Cyp2c38 as a marker, Figure 4.3D) and 
reduced colonic concentrations of CYP monooxygenase-produced EpFAs (Figure 4.3E), 
supporting the involvement of CYP monooxygenase pathway in colon tumorigenesis.  
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Figure 4.3 Compared with Cyp2c+/+ mice, the AOM/DSS-induced colon 
tumorigenesis is reduced in Cyp2c+/- mice.  
(A) Scheme of animal experiment. (B) Quantification of colon tumorigenesis. (C) H&E 
histology, and immunohistochemical staining of PCNA and β-catenin in colon. (D) 
Expression of pro-inflammatory and pro-tumorigenic genes, and Cyp monooxygenase 
(using Cyp2c38 as a marker) in colon. (E) Concentrations of CYP monooxygenase-
produced metabolites in colon. 
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4.4.5 Pharmacological inhibition of CYP monooxygenases suppresses AOM/DSS-
induced colon tumorigenesis 
We tested the effects of two different CYP monooxygenase inhibitors, SKF-525A and 
clotrimazole 102,103, on AOM/DSS-induced colon tumorigenesis in mice. Since the 
mutagenic activity of AOM requires metabolic activation by Cyp2e1 101, we initiated 
treatment of SKF-525A and clotrimazole after the AOM and DSS treatment (see animal 
experiment scheme in Figure 4.4A). We found that oral administration of these two 
inhibitors suppressed AOM/DSS-induced colon tumorigenesis in mice (Figure 4.4B). 
Furthermore, treatment with these two inhibitors reduced expression of PCNA (a marker 
of cell proliferation), increased expression of cleaved caspase-3 (a marker of cell 
apoptosis), and decreased expression of pro-inflammatory and pro-tumorigenic genes 
(Tnf-α, Mcp-1, Il-6, Il-1β, Ifn-γ, Axin2, and Cox-2), in colon tumors (Figure 4.4C-D). 
These results support that pharmacological inhibition of CYP monooxygenases 
suppressed AOM/DSS-induced colon tumorigenesis.  
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Figure 4.4 Pharmacological inhibition of CYP monooxygenases suppresses 
AOM/DSS-induced colon tumorigenesis in mice.  
(A) Scheme of animal experiment. (B) Quantification of colon tumorigenesis. (C) 
Immunohistochemical staining of PCNA and cleaved caspase-3 in the colon. (D) 
Expression of pro-inflammatory and pro-tumorigenic genes in the colon. Abbreviations: 
Clo: clotrimazole; SKF: SKF-525A. 
 
4.4.6 Treatment with EpOME, but not other CYP monooxygenase metabolites, 
increases inflammation and JNK phosphorylation in macrophage cells and colon 
cancer cells 
To determine the specific metabolites involved in the colon cancer-enhancing effects of 
CYP monooxygenases, we studied the biological actions of CYP monooxygenase 
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metabolites. The ω-6-series CYP metabolites, including EpOMEs produced from LA and 
EETs produced from ARA, are the most abundant EpFAs in the plasma and tissues, 
therefore, we focused on these metabolites. Treatment with 9,10- and/or 12,13-EpOME 
(concentration = 100 nM) increased gene expression of pro-inflammatory cytokines in 
mouse macrophage RAW 265.7 cells and human colon cancer HCT-116 cells (Figure 
4.5A-C). In contrast, other types of CYP metabolites, including the down-stream 
metabolites of EpOMEs termed 9,10- and 12,13-dihydroxyoctadecenoic acid (DiHOME) 
or CYP metabolites derived from other fatty acids, such as 11,12- and 14,15-EET, had no 
such effects (Figure 4.5A-C). 
 
Since 12,13-EpOME showed that most potent effect to induce inflammation in vitro, we 
further studied this metabolite. Treatment with 12,13-EpOME (concentration = 1-100 
nM) increased gene expression of Il-6 and Mcp-1 in a dose-dependent manner in RAW 
265.7 cells (Figure 4.5D). ELISA analysis further validated that 12,13-EpOME increased 
protein levels of IL-6 and MCP-1 in RAW 265.7 cells (Figure 4.5E). Consistent with its 
enhancing effect on inflammation, 12,13-EpOME induced a rapid phosphorylation of 
JNK (Figure 4.5F). Similar results were also observed in colon cancer HCT-116 cells 
(Figure 4.5G-H). Together, these results demonstrate that 12,13-EpOME had pro-
inflammatory effects in vitro. 
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Figure 4.5 EpOME increases inflammation in vitro. 
(A-B) Effect of EpOMEs, DiHOMEs and EETs (concentration = 100 nM) on gene 
expression of Il-6 and Mcp-1 in mouse macrophage RAW 265.7 cells. (C) Effect of 
EpOMEs, DiHOMEs and EETs (concentration = 100 nM) on gene expression of IL-6 in 
human colon cancer HCT-116 cells. (D) Dose-response effect of 12,13-EpOME on gene 
expression of Il-6 and Mcp-1 in RAW 265.7 cells. (E) Effect of 12,13-EpOME on 
medium concentrations of IL-6 and MCP-1 in RAW 265.7 cells. (F) Effect of 12,13-
EpOME on phosphorylation of JNK in RAW 265.7 cells. (G) Dose-response effect of 
12,13-EpOME on gene expression of IL-6 and MCP-1 in HC-T116 cells. (H) Effect of 
12,13-EpOME on phosphorylation of JNK in HCT116 cells. 
 
4.4.7 Treatment with EpOME exaggerates AOM/DSS-induced colon tumorigenesis 
in vivo 
We determined the actions of 12,13-EpOME on colon tumorigenesis in vivo. To this end, 
we stimulated mice with AOM/DSS to induce colon tumors, then treated the mice with 
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12,13-EpOME or vehicle via Alzet® osmotic mini-pumps (Figure 4.6A). Compared with 
vehicle-treated AOM/DSS mice, the 12,13-EpOME-treated AOM/DSS mice had 
increased tumor number, tumor size, and total tumor burden, illustrating exacerbated 
colon tumorigenesis (Figure 4.6B). Consistent with the increased colon tumorigenesis, 
treatment with 12,13-EpOME enhanced infiltration of CD45+ and CD45+ F4/80+ immune 
cells, increased expression of pro-inflammatory and pro-tumorigenic genes (Tnf-α, Il-1β, 
and Axin2), and upregulated expression of tumorigenic markers (PCNA and β-catenin), 
in the colon tumor (Figure 4.6C-E). Together, these results demonstrate that 12,13-
EpOME has enhancing effects on colon tumorigenesis in vivo. 
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Figure 4.6 EpOME exaggerates AOM/DSS-induced colon tumorigenesis in vivo. 
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(A) Scheme of animal experiment to test the effect of 12,13-EpOME (dose = 2 
mg/kg/day, administered via mini-pump) on colon tumorigenesis. (B) Quantification of 
colon tumorigenesis in mice. (C) Expression of pro-inflammatory and pro-tumorigenic 
genes in colon. (D) Quantification of CD45+ and CD45+ F4/80+ immune cells in colon. 
(E) H&E histology, and immunohistochemical staining of PCNA and β-catenin in colon. 
 
 
4.5 Discussion 
 
Colon cancer is the third most common cancer and the second leading cause of cancer-
related death in United States 6, emphasizing the need for discovery of novel cellular 
targets which are crucial in the pathogenesis of colon cancer. Using a LC-MS/MS-based 
targeted metabolomics, the central finding of our research is that EpFAs, which are 
eicosanoid metabolites produced by CYP monooxygenases, are significantly elevated in 
both the circulation and colon tissues of the AOM/DSS-induced colon cancer mice. On 
the basis of this finding, we further demonstrate that CYP monooxygenases are 
overexpressed in colon cancer and play critical roles in colon tumorigenesis. Together, 
our findings demonstrate that the previously unappreciated CYP/EpFA axis is 
upregulated in colon cancer, contributes to its pathogenesis, and could be therapeutically 
explored for preventing or treating colon cancer. 
 
Here we show that CYP monooxygenase-produced EpFAs are increased in both plasma 
and colon of the AOM/DSS-induced colon cancer mice. A previous study showed that in 
DSS-induced colitis models, the circulating concentrations of EpFAs were not changed 
36. Together, these results suggest that colon tumor, but not colonic inflammation, induces 
the CYP monooxygenase pathway. There could be many mechanisms by which the CYP 
monooxygenases are overexpressed in colon tumors. The expression of CYP 
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monooxygenases has been shown to be elevated by hypoxia 3, which is a common feature 
of tumor tissues 37. Therefore, the hypoxic tumor microenvironment could contribute to 
the increased expression of CYP monooxygenases in tumor tissues. To date, the 
expression pattern of CYP monooxygenases in human colon tumor tissues are not well 
understood. Only one study has investigated their expressions in human colon tumor 
tissues, which showed that CYP2C9 is detected in 13 out of 17 human colon tumor 
samples, while it is not detected in matched benign samples 35. This result is in agreement 
with our finding, supporting that the CYP monooxygenase pathway is upregulated in 
human colon cancer. 
 
Our results support that EpOMEs are critical regulators of colon tumorigenesis. We show 
that EpOMEs are elevated in the circulation of mice with colon cancer; in addition, 
EpOMEs have direct and potent effects to induce inflammation and colon tumorigenesis 
in vitro and in vivo. A better understanding of the roles of EpOMEs in human colon 
cancer could help to develop EpOMEs as potential biomarkers of colon cancer, which 
could have important clinical implications. Previous studies, performed in other disease 
models, have shown that EpOMEs have an array of detrimental effects on human health. 
EpOMEs are elevated in the circulation of patients with severe burns, and are associated 
with multiple organ failure and adult respiratory distress syndrome in these patients 
41,42,44,104. In animal studies, treatment with high-dose EpOMEs induced pulmonary 
edema, lung injury, and cardio-depression 43,105,106. Together, these results support that 
EpOMEs could contribute to the pathogenesis of colon cancer, as well as other human 
diseases. 
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The tissue concentrations of EpOMEs are in part mediated by the levels of LA in 
membrane phospholipids 3. The consumption of LA, which is highly abundant in 
vegetable oil products (such as corn, soybean, and canola oils, as well as fried food, salad 
dressing, and mayonnaise), is very high in western countries 107. Substantial animal 
experiments showed that a high dietary intake of LA is associated with increased AOM-
induced colon tumorigenesis 62-66, but the underlying mechanisms are not well 
understood. Here our study showed that EpOMEs have potent effects to induce 
inflammation and colon tumorigenesis in vitro and in vivo, suggesting that EpOMEs 
could serve as a potential mechanistic linkage between overconsumption of LA and 
elevated risks of colon cancer. Validation of the roles of EpOMEs involved could help to 
design human studies to clarify the impact of LA consumption on colon tumorigenesis, 
which could lead to significant impact for public health.  
 
Using both pharmacological and genetic approaches, our results support that CYP 
monooxygenases could be a potential therapeutic target of colon cancer. Notably, we 
show that genetic ablation of Cyp2c monooxygenases reduces colonic concentrations of 
CYP monooxygenase-produced metabolites, and attenuates AOM/DSS-induced colon 
tumorigenesis. This finding is in agreement with our previous report, which showed that 
compared with WT mice, genetically engineered mice with endothelial overexpression of 
CYP2C8 monooxygenase (Tie2-CYP2C8 Tr mice) have enhanced  
xenograft tumor growth of B16F10 melanoma and T241 fibrosarcoma 28. Together, these 
results support that targeting CYP monooxygenases could be a potential strategy to 
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inhibit colon cancer, as well as other types of cancer. Previous studies showed that some 
FDA-approved drugs are potent inhibitors of CYP monooxygenases 26, and these drugs 
could be repurposed for preventing or treating colon cancer; in addition, novel 
monooxygenase inhibitors could be developed for human translation. 
 
In conclusion, our study demonstrates that the previously unappreciated CYP 
monooxygenase pathway is upregulated in colon cancer, contributes to its pathogenesis, 
and could be therapeutically explored for preventing or treating colon cancer. A better 
understanding of its roles in colon tumorigenesis could help to develop novel therapeutic 
targets or biomarkers of colon cancer, facilitating the development of mechanism-based 
strategies to reduce the risks of colon cancer. 
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CHAPTER 5 
 
 Ω-3 POLYUNSATURATED FATTY ACIDS AND THEIR CYTOCHROME P450-
DERIVED METABOLITES SUPPRESS COLORECTAL TUMOR 
DEVELOPMENT IN MICE 
 
5.1 Abstract 
Many studies have shown that dietary intake of ω-3 polyunsaturated fatty acids (PUFAs) 
reduces the risks of colorectal cancer, however the underlying mechanisms are not well 
understood. Here we used a LC-MS/MS-based lipidomics to explore the roles of 
eicosanoid signaling in the anti-colorectal cancer effects of ω-3 PUFAs. Our results 
showed that dietary feeding of ω-3 PUFAs-rich diets suppressed growth of MC38 
colorectal tumor, and modulated profiles of fatty acids and eicosanoid metabolites in 
C57BL/6 mice. Notably, we found that dietary feeding of ω-3 PUFAs significantly 
increased levels of epoxydocosapentaenoic acids (EDPs, metabolites of ω-3 PUFA 
produced by cytochrome P450 enzymes) in plasma and tumor tissue of the treated mice. 
We further showed that systematic treatment with EDPs (dose = 0.5 mg/kg/day) 
suppressed MC38 tumor growth in mice, with reduced expressions of pro-oncogenic 
genes such as c-myc, Axin2, and C-jun in tumor tissues. Together, these results support 
that formation of EDPs might contribute to the anti-colorectal cancer effects of ω-3 
PUFAs. 
 
5.2 Introduction 
Every year, there are ~134,490 new cases and ~49,190 deaths from colorectal cancer, 
making colorectal cancer the second cause of cancer-related death in the United States 
108. Epidemiological and pre-clinical data support that dietary intake of ω-3 
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polyunsaturated fatty acids (PUFAs), which are abundant in fish and fish oil supplements, 
may reduce risks of colorectal cancer. In contrast, ω-6 PUFAs, which are commonly 
found in vegetable oils, are suggested to promote colorectal cancer 66,109-113. This is 
important because a typical Western diet contains 30-50 times more ω-6 than ω-3 
PUFAs, though a ratio of ω-6-to-ω-3 PUFAs of 1:1 was recommended for human 
consumption by many nutritional panels 114. Therefore, it is of critical importance to 
validate the effects and mechanisms of ω-3 PUFAs on colorectal cancer, which might 
help to effectively implement ω-3 PUFAs for colorectal cancer prevention.  
 
A general mechanism to explain the health benefits of ω-3 PUFAs is that they compete 
with arachidonic acid (ARA, 20:4ω-6) for the enzymatic metabolism by cyclooxygenase 
(COX), lipoxygenase (LOX), and cytochrome P450 (CYP) enzymes, leading to reduced 
formation of ω-6-series eicosanoids which are predominately pro-inflammatory and pro-
tumorigenic, and increased formation of ω-3-series eicosanoid metabolites which are 
less-detrimental or even beneficial 5. Recent research showed that ω-3 PUFAs, such as 
eicosapentaenoic acid (EPA, 20:5ω-3) and docosahexaenoic acid (DHA, 22:6ω-3), are 
highly efficient alternative substrates of CYP enzymes 4, while they are known as 
relatively poor substrates of COX and LOX enzymes 115. Notably, emerging animal and 
human studies showed that the CYP pathway is the dominant pathway in metabolizing ω-
3 PUFAs in vivo 116,117. We showed that epoxydocosapentaenoic acids (EDPs), which are 
CYP metabolites of DHA, potently suppressed breast tumor growth and lung cancer 
metastasis through inhibiting angiogenesis in vivo 51. In agreement with our finding, a 
recent study by Yanai et al. showed that systematic treatment with EDPs inhibited 
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pathological angiogenesis in a mouse model of macular degeneration 27. Together, these 
studies suggest that the CYP metabolites of ω-3 PUFAs, such as EDPs, might play an 
important role in mediating the anti-cancer and anti-angiogenic effects of ω-3 PUFAs.  
 
Regarding colorectal cancer, previous studies have shown that eicosanoid metabolome is 
deregulated in colorectal cancer, and some eicosanoid biogenesis enzymes and associated 
metabolites play central roles in regulating colorectal cancer 19,118. However, how ω-3 
PUFAs modulate eicosanoid signaling in colorectal cancer is poorly characterized, in 
addition, the actions of ω-3 PUFAs-derived eicosanoid metabolites on colorectal cancer 
are largely unknown. Here we used a LC-MS/MS-based lipidomics to explore the roles of 
eicosanoid signaling in the anti-colorectal cancer effects of ω-3 PUFAs, using a xenograft 
MC38 colorectal cancer model in C57BL/6 mice. Our results showed that dietary feeding 
of ω-3 PUFA-rich diets suppressed growth of colorectal tumor, and increased levels of 
EDPs in plasma and tumor tissue of the treated mice. We further found that systematic 
treatment with EDPs inhibited growth of colorectal cancer in mice. Together, these 
results support that formation of EDPs could might to the anti-colorectal cancer effects of 
ω-3 PUFAs. 
 
5.3 Materials and Method 
5.3.1 Animal experiment of ω-3 PUFA-rich diet on MC38 colorectal cancer growth 
All procedures of animal care were performed in accordance with the protocols approved 
by the Institutional Animal Care and Use Committee of the University of Massachusetts. 
Male C57BL/6 mice (age = 6 weeks) were purchased from Charles River Laboratories 
(Wilmington, MA). The mice were pre-fed with experimental diets for three weeks, then 
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400,000 MC38 colorectal cancer cells (a gift from Prof. Ajit Varki at UCSD) in 100 μL 
PBS were subcutaneously injected into each mouse to initiate primary tumor growth. 
Tumor sizes were measured using a caliper; after 15 days of cancer cell injection, the 
mice were sacrificed and the tumor tissues were dissected, weighted and subjected to 
biochemical analysis. We used three experimental diets to study the effects of ω-3 
PUFAs on colorectal cancer: control ω-6 diet (ratio of ω-6-to-ω-3 PUFA is ≈ 69.3:1), ω-3 
diet (ratio of ω-6-to-ω-3 PUFA is ≈ 1.26:1), and ω-3-high diet (ratio of ω-6-to-ω-3 PUFA 
is ≈ 0.56:1). 
 
5.3.2 Lipidomics analysis 
After animal sacrifice, the tumor tissues, colon tissues and plasma were harvested and 
subjected to LC-MS/MS-based lipidomics analysis. For plasma lipid metabolite 
extraction, about 250 μL plasma were mixed with deuterated internal standards, then 
loaded onto pre-washed Waters® Oasis solid phase extraction (SPE) cartridges, washed 
with 95:5 water/methanol with 0.1% acetic acid, the analytes were eluted with methanol 
and ethyl acetate, dried using a centrifugal vacuum evaporator, then reconstituted in 
methanol for LC-MS/MS analysis. For tumor lipid metabolite extraction, about 100 mg 
tissues were mixed with an antioxidant solution (0.2 mg/mL butylated hydroxytoluene 
and 0.2 mg/mL triphenylphosphine in methanol), the deuterated internal standards, and 
400 μL extract solution (0.1% acetic acid with 0.2 mg/mL butylated hydroxytoluene in a 
methanol solution), were homogenized; the resulting homogenates were kept in −80 °C 
overnight. After centrifugation of the homogenates, the pellets were washed with 
methanol (containing 0.1% butylated hydroxytoluene and 0.1% acetic acid) and then 
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combined with the supernatant. The lipid metabolites in the combined solutions were 
extracted using SPE columns, similar to the description above for the plasma lipid 
metabolite extraction. The LC-MS/MS analysis were carried out on an Agilent 1200SL 
HPLC system (Agilent, Santa Clara, CA) coupled to a 4000 QTRAP MS/MS (AB Sciex, 
Foster City, CA) as described in our previous report 18. The peaks were identified 
according to the retention time and specific multiple reaction monitoring (MRM) 
transitions of the lipid metabolite standards. The concentrations of the lipid metabolites 
are calculated against the calibration curve with standards. 
 
5.3.3 Flow cytometry analysis 
After animal sacrifice, the dissected tumor tissues were digested using enzymatic 
degradation solution (500 μg/ml collagenase, 500 μg/ml DNase, 100 μg/ml 
Hyaluronidase in HBSS) for 2 hours at room temperature, filtered through 70 μm cell 
sorters (BD Biosciences) to obtain single cell suspension, which were stained with FITC-
conjugated anti-mouse CD45 antibody, APC-conjugated anti-mouse CD31 antibody, 
APC/Cy7 anti-mouse Ly-6G/Ly-6C (Gr-1) antibody, PerCP/Cy6.5-conjugated anti-
mouse F4/80 antibody or isotype control antibody (R&D Systems). The stained cells 
were analyzed using BD LSRFortessa™ cell analyzer (BD Biosciences) and data were 
processed using FlowJo software. Endothelial cells were identified as CD45-, CD31+ 
cells, neutrophils were identified as CD45+, Gr1+ cells and macrophage were identified 
as CD45+, F4/80+ cells. 
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5.3.4 Animal experiment of EDPs on MC38 colorectal cancer growth 
To test the effect of EDPs on colorectal cancer growth, C57BL/6 male mice were 
subcutaneously implanted with Osmotic mini-pumps (Durect, Cupertino, CA, catalog 
number 1004), which contained vehicle (a 1:1 vol/vol mixed solution of DMSO and PEG 
400) or EDPs (dose of EDPs = 0.5 mg/kg body weight/day). After one week of mini-
pump implantation, 400,000 MC38 colorectal cancer cells in 100 μL PBS were 
subcutaneously injected into each mouse to initiate primary tumor growth. Tumor sizing 
was measured using caliper, at the end of the experiment, the tumors were dissected, 
weighted and subjected to biochemical analysis. The EDPs are a mixture containing EDP 
regioisomers (7,8-, 10,11-, 13,14-, 16,17-, and 19,20-EDP), as we described 19. 
 
5.3.5 Real-time PCR (RT-PCR) analysis 
Total RNA was isolated from tumor tissues using TRIzol Reagent (Life technologies, 
Carlsbad, CA) according to manufacturer’s instruction. Conversion of up to 2 μg of total 
RNA to single stranded cDNA was preformed using High-Capacity cDNA Reverse 
Transcription Kit (Life technologies, Carlsbad, CA) according to manufacturer’s 
instruction. Quantitative RT-PCR was conducted using Maxima SYBR Green/ROX 
qPCR Master Mix (Thermo Fisher Scientific, Agawam, MA) on a DNA Engine 
Opticon® 2 System (Bio-Rad Laboratories, Hercules, CA) with specific mouse primers. 
The primers used in this research were: C-myc (sense) 5’-
ATGCCCCTCAACGTGAACTTC-3’ and (antisense) 5’-
GTCGCAGATGAAATAGGGCTG-3’, 
 67 
Axin2 (sense) 5’-TGACTCTCCTTCCAGATCCCA-3’ and (antisense) 5’-
TGCCCACACTAGGCTGACA-3’, C-jun (sense) 5’-CCTTCTACGACGATGCCCTC-3’ 
and (antisense) 5’-GGTTCAAGGTCATGCTCTGTTT-3’, The results of target genes 
were normalized to Gapdh gene and expressed to the control group mice using the 2-
ΔΔCt method. 
The primer to analyze Gapdh is (sense) 5’-AGGTCGGTGTGAACGGATTTG-3’ and 
(antisense) 5’-TGTAGACCATGTAGTTGAGGTCA-3’. 
 
5.3.6 Data Analysis 
All data are expressed as the mean ± standard error of the mean (SEM). Differences 
among Control, DHASCO and DHASCO-high diet feeding group were analyzed by one-
way ANOVA and pairwise multiple comparisons among groups were performed by using 
Dunn's test. For the comparison between the control group and EDP group, Shapiro-Wilk 
test was used to verify the normality of data. When data were normally distributed, 
statistical significance was determined using two-side t-test; otherwise, significance was 
determined by Mann-Whitney U test. P values less than 0.05 are reported as statistically 
significant. All of these data analysis was performed by using SigmaPlot software (San 
Jose, CA). 
 
5.4 Results 
5.4.1 ω-3 PUFAs-rich diets inhibit growth of MC38 colorectal tumor in mice 
We prepared three completely defined isocaloric diets containing 10 wt/wt% total fat. For 
the control diet, corn oil was the only source of dietary fat, with a ratio of ω-6-to-ω-3 
PUFAs in the diet = 69.3:1, to mimic a typical Western diet. For the DHASCO diet, the 
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fat component was a mixture of 38% corn oil and 62% DHA-rich DHASCO® Algae oil, 
with a ratio of ω-6-to-ω-3 PUFAs = 1.26:1. For the DHASCO-high diet, the fat 
component was a mixture of 20.7% corn oil and 79.3% DHASCO® oil, with a ratio of ω-
6-to-ω-3 PUFAs = 0.56:1. We have designed these two ω-3 PUFAs-rich diets, since a 
ratio of ω-6-to-ω-3 PUFAs ≈ 1:1 was recommended for human consumption by 
nutritionists 119. 
 
To study the effect of ω-3 PUFAs on MC38 colorectal tumor growth, we pre-fed 6-week-
old C57BL/6 mice with these three experimental diets for three weeks, then 
subcutaneously injected MC38 colorectal cancer cells into mice to initiate growth of 
colorectal tumor (see animal experimental scheme in Figure 5.1A). Compared with 
control diet, both DHASCO and DHASCO-high diets suppressed growth of MC38 
colorectal tumor in mice with similar inhibitory effects: at the end of the experiment, 
these two ω-3 PUFAs-rich diets caused a ~50% reduction of tumor weight (P < 0.05, 
Figure 5.1B-D). Flow cytometry analysis of the single cell suspension from the dissected 
MC38 tumors showed that these two ω-3 PUFAs-rich diets reduced the presence of 
endothelial cells (CD31+, CD45-) in tumor tissues, suggesting that dietary feeding of ω-3 
PUFAs suppressed tumor angiogenesis (P < 0.05, Figure 5.1E). Together, these results 
are in agreement with previous studies for the anti-cancer and anti-angiogenic effects of 
ω-3 PUFAs.   
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Figure 5.1 Dietary feeding of ω-3 PUFAs-rich diets suppressed growth of MC38 
colorectal tumor, and tumor angiogenesis in C57BL/6 mice. 
(A) scheme of animal experiment, (B) time-course of MC38 tumor sizing, (C) 
quantification of tumor weight, (D) representative image of dissected MC38 tumors, (E) 
flow cytometry quantification of endothelial cells in MC38 tumors. 
 
5.4.2 ω-3 PUFAs-rich diets modulated fatty acid profiles in MC38 colorectal tumors 
We used GC-MS to analyze the profiles of fatty acids in the dissected MC38 colorectal 
tumors. Dietary feeding of the DHASCO diet (ratio of ω-6-to-ω-3 PUFAs = 1.26:1) 
significantly reduced levels of ω-6 PUFAs such as ARA, and increased levels of ω-3 
PUFAs such as EPA and DHA in MC38 tumor tissues. Notably, the level of ARA in 
MC38 colorectal tumor tissues was reduced from 9.96 ± 1.71% (mean ± SEM, from mice 
fed on control diet, the result was expressed as % of ARA to the total fatty acids in MC38 
tumor tissues) to 2.89 ± 0.38% (from mice fed on DHASCO diet, P < 0.01), representing 
a ~70% reduction of ARA in tumor tissues. The level of EPA was increased from 0 ± 0 % 
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to 1.27 ± 0.19% (P < 0.001), and the level of DHA was increased from 0.91 ± 0.16% to 
8.33 ± 1% (P < 0.001). In contrast, the levels of other PUFAs, such as linoleic acid (LA, 
18:2ω-6) and α-linoleic acid (ALA, 18:3ω-3), were not significantly changed in the tumor 
tissues. Together, these results showed that dietary feeding of ω-3 PUFAs-rich diet 
modulated profiles of PUFAs in MC38 colorectal tumor tissues, with reduced ARA and 
increased EPA and DHA. 
 
5.4.3 ω-3 PUFAs-rich diets modulated profiles of eicosanoid metabolites in plasma 
and tumor tissues 
After demonstrating that dietary feeding of ω-3 PUFAs-rich diets modulated tissue 
profiles of ARA, EPA, and DHA, which are important precursors to generate eicosanoid 
metabolites 5,  we studied the impacts of ω-3 PUFAs-rich diets on profiles of eicosanoid 
metabolites in the treated mice. To this end, we used a LC-MS/MS-based lipidomics 
approach to analyze the profiles of eicosanoid metabolites extracted from plasma, MC38 
tumor, and colon tissues of the treated mice. Our LC-MS/MS method can analyze > 100 
eicosanoid metabolites (see complete list of the eicosanoid metabolites analyzed by our 
method in Table 3.1). 
 
The LC-MS/MS analysis successfully quantified 58, 44, and 44 eicosanoid metabolites in 
plasma, MC38 tumor, and colon tissues, respectively; and some metabolites were below 
the detection limits of our LC-MS/MS method. The detected compounds included 
eicosanoid metabolites produced by COX, LOX, and CYP enzymes from LA, ALA, 
ARA, EPA, and DHA 86, allowing us to systematically analyze the effects of ω-3 PUFAs 
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on eicosanoid metabolome. A general trend was that dietary feeding of ω-3 PUFAs-rich 
diets reduced levels of ω-6-series metabolites, and increased levels of ω-3-series 
metabolites in plasma and tissues, which is in agreement with previous studies 5. The 
details of the LC-MS/MS profiling are described below. 
 
The CYP epoxygenases (mainly CYP2C and CYP2J isoforms) convert ARA, EPA, and 
DHA to fatty acid epoxides termed epoxyeicosatrienoic acids (EETs), 
epoxyeicosatetraenoic acids (EEQs), and EDPs respectively, which are further 
metabolized by soluble epoxide hydrolase (sEH) to generate the corresponding fatty acid 
diols (see scheme of CYP pathway in Figure 5.2A) 3. In the mice fed with control diet (ω-
6 PUFAs-rich), ARA-derived EETs are among the most abundant fatty acid epoxides in 
plasma (Figure 5.2B). In contrast, in the plasma of mice fed with DHASCO and 
DHASCO-high diets, there was a dramatic reduction of EETs and an increase of EPA-
derived EEQs and DHA-derived EDPs; notably, DHA-derived EDPs were among the 
most abundant fatty acid epoxides in plasma (Figure 5.2B). Consistent with the trend of 
fatty acid epoxides, dietary feeding of ω-3 PUFAs-rich diets also reduced ARA-derived 
fatty acid diols termed dihydroxyeicosatrienoic acids (DHETs), and enhanced EPA-
derived dihydroxyeicosatetraenoic acids (DiHETEs) and DHA-derived 
dihydroxydocosapentaenoic acids (DiHDPEs) (see Figure 5.2B). Similar to the profiles of 
eicosanoid metabolites in plasma, we also found that dietary feeding of ω-3 PUFAs-rich 
diets reduced levels of ARA-derived fatty acid epoxides and diols, and increased levels of 
EPA- and DHA-derived epoxides and diols in MC38 tumor and colon tissues (Figure 
5.2C-D). 
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Figure 5.2 Dietary feeding of ω-3 PUFAs-rich diets modulated profiles of eicosanoid 
metabolites in mice. 
(A) scheme of CYP pathway. (B) plasma, (C) MC38 tumor, and (D) colon profiles of 
CYP-derived fatty acid epoxide and diols. 
 
Besides the CYP pathway, we also analyzed eicosanoid metabolites produced by COX 
and LOX enzymes, many of these metabolites play central roles in regulating 
inflammation and tumorigenesis. For COX pathway, dietary feeding of ω-3 PUFAs-rich 
diets reduced levels of ARA-derived prostaglandins, notably, ω-3 PUFAs caused ~80% 
reduction of prostaglandin E2 (PGE2), which has potent pro-inflammatory and pro-
tumorigenic actions, in both MC38 tumor and colon tissues (Figure 5.3A-C). For LOX 
pathway, dietary feeding of ω-3 PUFAs-rich diets reduced ARA-derived hydroxyl fatty 
acids such as 11- and 15-hydroxyeicosatetraenoic acid (HETE), and increased EPA-
derived 5- and 15-hydroxyeicosapentaenoic acid (HEPE) (see Figure 5.3D-F). Together, 
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these results showed that dietary feeding of ω-3 PUFAs-rich diets caused a profound 
change of the eicosanoid metabolome, with reduced levels of ARA-derived metabolites, 
and increased levels of EPA- and DHA-derived metabolites. 
 
Figure 5.3 Dietary feeding of ω-3 PUFAs-rich diets modulated profiles of eicosanoid 
metabolites from COX and LOX pathway in mice. 
(A) Plasma, (B) MC38 tumor, and (C) Colon profiles of COX-derived prostaglandins and 
thromboxanes. (D) plasma, (E) MC38 tumor, and (F) colon profiles of LOX-derived 
metabolites. 
 
5.4.4 EDPs suppressed growth of MC38 tumor growth in vivo 
Given that dietary feeding of ω-3 PUFAs-rich diets dramatically increased concentrations 
of EDPs in plasma and tissues, we tested the effect of EDPs on MC38 tumor growth in 
C57BL/6 mice. Continuous infusion of synthetic EDPs (dose = 0.5 mg/kg/day) inhibited 
MC38 tumor growth in C57BL/6 mice, with ~50% reduction of tumor weight (Figure 
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5.4A-B). Flow cytometry of the single cell suspension from the dissected MC38 tumors 
showed that EDPs slightly reduced infiltration of neutrophils and macrophages into 
tumor tissues (P < 0.05, Figure 5.4C). RT-PCR analysis showed that EDPs reduced 
expressions of several genes related to cellular kinetics and tumorigenic Wnt pathway, 
such as c-myc, Axin2, and C-jun (Figure 5.4D), which are consistent with the anti-tumor 
effect of EDPs. 
Ctrl EDP
% 
of 
ma
cro
ph
ag
es
0
2
4
6
8
10
Ctrl EDP
% 
of 
ne
utr
op
hils
0
2
4
6
8
10
12
* *
Treatment time (day)
0 5 10 15 20
Tu
mo
r v
olu
me
 (m
m3
)
0
200
400
600
800
1000
1200
1400
1600
1800 Ctrl
EDP
Ctrl EDP
Tu
mo
r w
eig
ht 
(m
g)
0
500
1000
1500
2000
*
A                                              B                                               C                        
Ctrl EDP
Re
lat
ive
 ge
ne
 ex
pre
ss
ion
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4 C-Jun
Ctrl EDP
Re
lat
ive
 ge
ne
 ex
pre
ss
ion
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Axin 2
Ctrl EDP
Re
lat
ive
 ge
ne
 ex
pre
ss
ion
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Ctrl EDP
Axin2 C-junC-mycD                  
*
*
*
 
Figure 5.4 Treatment with synthetic EDPs suppressed growth of MC38 tumor in 
C57BL/6 mice. 
(A) time-course of MC38 tumor sizing, (B) representative images of dissected MC38 
tumors, and quantification of tumor weight, (C) flow cytometry analysis of immune cells 
in MC38 colon tumors, and (D) RT-PCR analysis of pro-oncogenic genes in MC38 
tumors. 
 
5.5 Discussion 
To date, there is a fair amount of studies to demonstrate the anti-colorectal cancer effects 
of ω-3 PUFAs 66,109-113; however, the underlying mechanisms remain largely unknown. A 
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general theory to explain the health benefits of EPA and DHA is that they can efficiently 
compete with ARA at almost every step of eicosanoid biogenesis, leading to reduced 
formation of ARA-derived eicosanoids which are predominately pro-inflammatory and/or 
pro-tumorigenic, and increased formation of EPA- and DHA-derived metabolites which 
have less-detrimental or beneficial actions 5. Here we used a LC-MS/MS-based 
lipidomics to explore the roles of eicosanoid signaling in the anti-colorectal cancer effects 
of ω-3 PUFAs. The LC-MS/MS analysis showed that dietary feeding of ω-3 PUFA-rich 
diets caused a dramatic modulation of the eicosanoid profiles in circulation and in 
colorectal tumor tissues, with reduced levels of ω-6-series metabolites and increased 
levels of ω-3-series metabolites. A central finding of our study is that dietary feeding of 
ω-3 PUFAs-rich diets dramatically increased levels of EDPs in both plasma and MC38 
colorectal tumor of the treated mice. In addition, systematic treatment with EDPs 
suppressed growth of MC38 colorectal tumor in mice. Together, these results support that 
formation of EDPs could contribute the anti-colorectal cancer effects of ω-3 PUFAs, and 
EDPs might serve as a biomarker for the anti-cancer effects of ω-3 PUFAs. 
 
Regarding the biological effects of EDPs, our results further support the anti-cancer 
effects of EDPs. Our previous study showed that stabilized EDPs suppressed breast 
tumor growth and Lewis lung carcinoma metastasis in mice 51. However, in our previous 
study, co-administration of a pharmacological inhibitor of soluble epoxide hydrolase 
(sEH, the major enzyme in degrading EDPs) was required to stabilize low-dose EDP 
(dose of EDP = 0.05 mg/kg/day in our previous study) in circulation, in order to 
demonstrate the anti-cancer and anti-metastatic effects of EDP in vivo 51. Based on our 
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previous study, here we hypothesize that administration of EDP alone, at a higher dose, 
inhibits tumor growth in mice. Indeed, our result showed that administration of EDPs 
alone, at a higher dose than that of our previous experiment (dose of EDPs in this study = 
0.5 mg/kg/day), significantly inhibited MC38 colorectal tumor growth in mice, further 
validating the anti-cancer effects of EDPs in vivo. Several animal and human studies have 
shown high levels of EDPs in circulation upon dietary intake of ω-3 PUFAs 116,117, 
supporting that EDPs could serve as a reliable biomarker for exposure to ω-3 PUFAs. A 
limitation of current study is that we only tested the effects of exogenously administered 
EDPs, the biological effects of endogenous EDPs remain largely unknown. Further 
studies are needed to better characterize the actions of EDPs, in order to facilitate the 
development of potential biomarkers of ω-3 PUFAs.   
 
Many studies support that ω-3 PUFAs reduce the risks of colon inflammation 120-122 and 
colon cancer 66,109-113. However, there are inconsistent results from animal and human 
studies, which showed that ω-3 PUFAs had no effect 123,124 or detrimental effects 125,126, 
making it difficult to implement ω-3 PUFAs for disease prevention. The mixed results for 
the health-promoting effects of ω-3 PUFAs is a major barrier to effectively implement ω-
3 PUFAs for disease prevention. Based on our studies, polymorphisms in the genes 
encoding enzymes in CYP pathway may affect the metabolism of ω-3 PUFAs 127-133, 
impacting the generation of bioactive lipid metabolites, and thereby contributing to 
observed inter-individual variations to ω-3 PUFA supplementation 134. For example, 
based on our findings, people carrying Lys55Arg and Cys154Tyr mutations of soluble 
epoxide hydrolase (sEH, the major enzyme to degrade EDPs), which lead to higher sEH 
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enzymatic activities 133, might have lower tissue levels of EDPs, and thus poorer anti-
cancer responses upon dietary ω-3 PUFA supplementation. Such mechanistic knowledge, 
together with utilization of nutrigenomic and metabolomic approaches, could lead to 
targeted human trials to better understand the metabolic individuality and nutrition effects 
of ω-3 PUFAs 134,135. 
 
In conclusion, our studies showed that dietary feeding of ω-3 PUFAs-rich diets 
dramatically modulated profiles of eicosanoid metabolites in a mouse model of colorectal 
cancer. Among the altered eicosanoid metabolites, DHA-derived EDPs could play critical 
roles in mediating the anti-colorectal cancer effects of ω-3 PUFAs. A limitation of our 
study is that we used a xenograft model of MC38 colorectal cancer, which has many 
limitations to mimic the complicated process of colorectal carcinogenesis. In addition, we 
only studied the biological effects of exogenously administered EDPs. Further studies are 
needed to better characterize the roles of EDPs in health benefits of ω-3 PUFAs, in order 
to establish potential biomarkers for effective implementation of ω-3 PUFAs. 
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CHAPTER 6 
 
SUMMARY  
 
Enzymatic metabolism of polyunsaturated fatty acids leads to formation of bioactive 
LMs. Previous studies have shown that obesity leads to deregulation of LMs in adipose 
tissues. However, most previous studies have focused on single or limited number of 
LMs, few systematical analyses have been carried out. In Research Project 1, we 
conducted a LC-MS/MS-based lipidomics analysis of HFD-induced obesity in mice. Our 
central finding in Research Project 1 is that HFD significantly modulated the profiles of 
LMs in adipose tissues of mice. Among the three major PUFA metabolizing pathways 
(COX, LOX and CYP), CYP-derived fatty acid epoxides are the most dramatically 
changed LMs in adipose tissues of HFD-induced obesity. Almost all types of fatty acid 
epoxides, including EpOMEs derived from LA, EETs from ARA, EpDPEs from DHA, 
and EpODEs from α-LA, were reduced by 70-90% in different types of adipose tissues. 
Consistent with the reduced levels of fatty acid epoxides, the gene expressions of several 
CYP monooxygenases, including Cyp2j5, Cyp2j6, and Cyp2c44, were significantly 
reduced in adipose tissues of high-fat diet-fed mice. Our results showed that CYP-derived 
fatty acid epoxides are the most responsive LMs in high-fat diet-induced obesity, 
suggesting that these novel LMs could play critical roles in pathology of obesity. This 
study lays the foundation to further investigate the functional roles of LMs in obesity, 
which could facilitate the development of novel biomarkers or therapeutic targets for 
obesity and obesity-associated diseases. 
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Colon cancer is the third most common cancer and the second leading cause of cancer-
related death in the United States. It is important to discover novel cellular targets which 
are crucial in the pathogenesis of colon cancer, which could facilitate development of 
mechanism-based strategies to reduce the risks of colon cancer. Previous research has 
shown that certain eicosanoid metabolites are deregulated in colon cancer and contribute 
to its pathogenesis. Notably, the most prominent cancer-associated eicosanoids are 
prostaglandins, which are produced by COX-2 that is overexpressed in most human colon 
cancer samples. However, the gastrointestinal and cardiovascular toxicities induced by 
COX-2 inhibitors have limited their clinical applications 22. Besides COX-2, the roles of 
other eicosanoid pathways in colon tumorigenesis are not well understood. In Research 
Project 2, we used a lipidomics approach to systematically profile eicosanoids in a well-
established AOM/DSS-induced colon cancer model in C57BL/6 mice, then use 
pharmacological and genetic approaches to validate the functional roles of identified 
metabolite in colon tumorigenesis. Our central finding in Research Project 2 is that 
EpFAs, which are eicosanoid metabolites produced by CYP monooxygenases, are 
significantly elevated in both the circulation and colon tissues of the AOM/DSS-induced 
colon cancer mice. On the basis of this finding, we further demonstrate that CYP 
monooxygenases are overexpressed in colon cancer and play critical roles in colon 
tumorigenesis. Together, our findings demonstrate that the previously unappreciated 
CYP/EpFA axis is upregulated in colon cancer, contributes to its pathogenesis, and could 
be therapeutically explored for preventing or treating colon cancer. 
Regarding colorectal cancer, previous studies and Specific Aim 2 have shown that 
eicosanoid metabolome is deregulated in colorectal cancer, and some eicosanoid 
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biogenesis enzymes and associated metabolites play central roles in regulating colorectal 
cancer 19,118. However, how ω-3 PUFAs modulate eicosanoid signaling in colorectal 
cancer is poorly characterized, in addition, the actions of ω-3 PUFAs-derived eicosanoid 
metabolites on colorectal cancer are largely unknown. In Research Project 3, we used a 
lipidomics approach to explore the roles of eicosanoid signaling in the anti-colorectal 
cancer effects of ω-3 PUFAs, using a xenograft MC38 colorectal cancer model in 
C57BL/6 mice. Our central finding in Research Project 3 is that dietary feeding of ω-3 
PUFAs-rich diets dramatically increased levels of EDPs in both plasma and MC38 
colorectal tumor of the treated mice. In addition, systematic treatment with EDPs 
suppressed growth of MC38 colorectal tumor in mice. Together, these results support that 
formation of EDPs could contribute the anti-colorectal cancer effects of ω-3 PUFAs, and 
EDPs might serve as a biomarker for the anti-cancer effects of ω-3 PUFAs. 
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APPENDIX B 
 
 TABLE OF ABBREVIATION 
 
 
Abbreviation Full Name 
CYP cytochrome P450 
sEH soluble epoxide hydrolase 
PUFAs polyunsaturated fatty acids 
EpFA epoxygenated fatty acids 
LMs lipid metabolites 
COX cyclooxygenase 
LOX lipoxygenase 
LA α-linolenic acid 
γ-LA γ-linolenic acid 
DGLA dihomo-γ-linolenic acid 
EPA eicosapentaenoic acid 
DHA docosahexaenoic acid 
HFD high-fat diet 
LTB4 leukotriene B4 
PGI2 prostacyclin 
EETs epoxyeicosatrienoic acids 
PTGIS prostacyclin synthase 
PTGES prostaglandin E synthase 
AOM azoxymethane 
DSS dextran sulfate sodium 
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